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(SEQ ID N0:07} 
1 mdgtikeals vvsddqslfd saygaaahlp kadmtasgsp dygqphkinp lppqqewinq 
61 pvrvnvkrey dhmngsresp vdcsvskcsk lvgggesnpm nynsymdekn gppppnmttn 
121 errvivpadp th1tqehvrq wlewaikeys lme1dtsffq nmdgkelckm nkedflratt 
181 lyntevllsh lsylressll aynttshtdq ssrlsvkedp sydsvrrgaw gnnmnsglnk 
241 spplggaqti sknteqrpqp dpyqilgpts srlanpgsgq iqlwqfllel lsdsanasci 
301 tHegtngefk mtdpdevarr wgerkskpnm nydklsralr yyydknimtk vhgkryaykf 
361 dfhgiaqalq phptessmyk ypsdisymps yhahqqkvnf vpphpssmpv tsssffgaas 
421 qyHtsptggi ~pnpnvp~hp nthvpshlgs yy 
FIG. 6 
(SEQ ID NO:OB} 
1 miqtvpdpaa hikealsvvs edqslfecay gtphlaktem tassssdygq tskmsprvpq 
61 qdHlsqppar vtikrnecnps qvngsrnspd ecsvakggkm vgs?dtvgmn ygsymeekhm 
121 pppnmttner rvivpadptl HstdhvrqHl ewavkeyglp dvn1llfqni dgkelckmtk 
181 ddfqrltpsy nadillshlh ylretplphl tsddvdkalq nsprlmharn tdl?yepprr 
241 sawtghghpt pqskaaqpsp stvpktedqr pqldpyqilg ptssrlanpg sgq1qlHqfl 
301 lellsdssns scitwegtng efkntdpdev arrwgerksk pnmnydklsr alryyydkni 
361 mtkvhgkrya ykfdfhgiaq alqphppess lykypsdlpy mgsyhahpqk mnfvaphppa 
421 lpvtsssffa apnpyHnspt ggiypntrlp tshmpshlgt yy 
FIG. 7 
SEQIDN0:01: 1 pgsgqiqlwq fllellsdsa nascitwegt ngefkmtdpd evarrwgerk 
skpnmnydkl sralryy~dk nimt~vhgkr l!Ykfdfhgi aqalqphp 98 
SEQ ID NO: 02 1 pgsgqiqlwq fllel:sdss nsscitwegt ngefkntdpd evarrwgerk skpnrrnydkl 
sralryy~dk nimt~vhgkr l!Ykfdfhgi aqalqphp 98 
FIG. 8 
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SEMI-SYNTHETIC MITHRAMYCIN 
DERIVATIVES WITH ANTI-CANCER 
ACTIVITY 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation application of PCT/ 
US2013/074725, filed Dec. 12, 2013, which claims the 
benefit of U.S. Provisional Application No. 61/737,353 filed 
Dec. 14, 2012, and this application claims the benefit of U.S. 
Provisional Application No. 62/001,516, filed May 21,2014. 
The entire disclosures of the foregoing PCT and Provisional 
Patent Applications are hereby incorporated by reference 
herein. 
SEQUENCE LISTING 
The instant application contains a Sequence Listing which 
has been submitted electronically in ASCII format and is 
hereby incorporated by reference in its entirety. Said ASCII 
copy, created on Jul. 23, 2015, is named 050229-
0635_SL.txt and is 12,125 bytes in size. 
TECHNICAL FIELD 
2 
Although ETS transcription factors such as FLil and 
ERG have been identified as critical targets in diseases such 
as Ewing sarcoma, no therapies have yet moved from bench 
to bedside that could impact the outcome of this disease. 
5 Ewing sarcoma, which affects primarily children and young 
adults is a difficult cancer to treat. Current therapy with a 
combination of severely cytotoxic drugs provides up to 60% 
long-term survival, but the cancer often recurs. 
Recently, mithramycin (MTM), an aureolic acid natural 
10 product previously used clinically against other cancers, was 
identified as a potent (low-nM) inhibitor of EWS-FLil in 
Ewing sarcoma cells (Grohar et a!., (2011) Journal of the 
National Cancer Institute 103, 962-78). MTM exhibited 
15 similar high potency against Ewing sarcoma tumor cells in 
vitro and was efficacious in Ewing sarcoma mouse xeno-
grafts. Based on this study, MTM entered clinical trials at the 
National Cancer Institute as a Ewing sarcoma therapeutic 
(Clinica!Trials.gov, ID#NCT01610570) in 2012. Despite its 
20 strong inhibitory properties towards Ewing sarcoma, MTM 
was found to be highly toxic to non-Ewing cells, apparently 
because it inhibits Sp transcription factors. Therefore, MTM 
analogues that are more selective against Ewing sarcoma 
cells and/or other cancers are needed. 
25 
The present disclosure relates to mithramycin side chain 
carboxylic acid (MTM SA) derivatives and their use in the 
treatment of cancers. The present disclosure also relates to 
methods for identifying MTM SA derivative compounds 30 
that selectively modulate the activity of a target ETS tran-
scription factor. 
It is clear that MTM has high potential in the fight against 
cancer and new and improved analogues would find clinical 
relevance. A need thus exists to improve the performance, 
selectivity and efficacy of MTM. 
SUMMARY OF THE DISCLOSURE 
In one aspect of the disclosure, certain MTM SA deriva-
tives or their pharmaceutically acceptable salts are provided. 
Such derivatives can be used in the treatment of various BACKGROUND 
35 cancers including Ewing sarcoma and various neuro-dis-
eases. In certain embodiments there are provided MTM SA 
derivatives having the following formula: 
All members of the erythroblast transformation-specific 
(ETS) transcription factor-family contain an Ets-domain 
which consists of approximately 80 amino acids with four 
tryptophan repeats. The Ets-domain binds to double-
stranded DNA of target genes containing a GGAA/T core 40 
motif and different flanking regions. Exemplary ETS tran-
scription factors include Friend leukemia integration 1 tran-
scription factor (FLil) and v-ets avian erythroblastosis virus 
E26 oncogene-like transcription factor (ERG). 
FLI1 aberrant regulation is often associated with malig- 45 
nant transformation and is associated with chromosomal or a pharmaceutically acceptable salt thereof; wherein Z 
represents 0, S, N-R'; R and R' represent, for each occur-
rence, H, alkyl, heterocyclic, aryl, heteroaryl, provided that 
R is not H when Z is 0; ZR taken together represents an 
abnormalities in humans. For example, in Ewing Sarcoma 
and primitive neuroectodermal tumors, a chromosomal 
translocation results in a chimeric EWS-FLI 1 fusion protein, 
containing the 5' region ofEWS (Ewing sarcoma breakpoint 
region 1) and the 3' ETS region of Fli-1 (Delattre et a!., 
Nature. 1992 Sep. 10; 359(6391):162-5). This oncoprotein 
acts as an aberrant transcriptional activator with strong 
transforming capabilities. FLil and homologous transcrip-
tion factors also have been implicated in human leukemias, 
such as Acute Myelogenous Leukemia (AML), involving 
loss or fusion of the tel gene, as well as other malignancies 
including clear-cell sarcoma, myxoid liposarcoma, desmo-
plastic small round cell tumor, myxoid chondrosarcoma, 
acute myeloid leukemia, congenital fibrosarcoma, prostate 
cancer and pancreatic cancer. 
Another ETS transcription factor, ERG, is implicated in 
several cancers. Aberrant ERG regulation has been shown to 
be associated with diseases including Ewing sarcoma, acute 
myeloid leukemia (AML), prostate cancer, acute lymphob-
latic leukemia (ALL), Alzheimer's disease (AD), and Down 
syndrome (DS). 
50 organic residue, e.g., an amino acid conjugate or its ester 
derivative; and wherein MTM1 represents the fused ring 
portion of the mithramycin structure and can include differ-
ent sugars or sugar chains. 
In certain embodiments, the MTM SA derivative is an 
55 amide derivative, e.g. ZR together form a NR1 R2 group 
where R1 and R2 can be the same or different and each of R1 
and R2 can be an H, an amino acid conjugate or an ester 
derivative thereof, a lower straight chain or branched alkyl. 
In other embodiments, the MTM SA derivative is an amino 
60 acid derivative, e.g. NR1 R2 together form an amino acid 
conjugate or an ester derivative thereof. In certain embodi-
ments, NR1R2 is the amino acid conjugate phenylalanine 
(e.g., MTM SA-Phe) or an ester derivative thereof. In other 
embodiments, NR1 R2 is the amino acid conjugate trypto-
65 pharr (e.g., MTM SA-Trp) or its ester derivative. The amino 
acid conjugate or its ester derivative thereof can further be 
substituted. Substituents include, for example, -R3 Y where 
US 9,447,135 B2 
3 
R3 is alkyl, e.g., C1_16 or C1_8 alkyl, andY is a formyl ene, 
expoxy, aryl, e.g., phenyl, heteroaryl, e.g., indolyl. In some 
embodiments -R3 Y together form an ally lox group. In 
another related embodiment, the MTM SA derivative 
includes one or more sugar groups such as D-digitoxose. In 
another related embodiment, the MTM SA derivative is 
MTM SA-Phe or MTM SA-Trp that also includes one or 
more different sugar moieties. 
In another aspect, the subject technology provides a 
method for screening MTM SA derivatives to identify 10 
derivatives that selectively complex with and specifically 
modulate the activity of a target ETS transcription factor that 
has a DNA binding domain with an amino acid sequence that 
is at least 85% identical to SEQ ID NO:Ol or SEQ ID N0:02 15 
over the entire length of either of these sequences. In a 
related embodiment, the screening method includes use of 
an isolated mutant ETS transcription factor described herein. 
In another related embodiment, the screening method 
includes the step of (a) contacting a mithramycin derivative 20 
as a test agent or a test agent other than mithramycin with a 
target ETS transcription factor in the presence of an oligo-
nucleotide substrate under conditions suitable for transcrip-
tion of the oligonucleotide substrate; (b) detecting the speci-
ficity of the test agent for binding to and/or modulating the 25 
activity of the target ETS transcription factor, and (c) 
selecting test agents that exhibit specifically for and modu-
late the activity of the target ETS transcription factor relative 
to a reference or control sample or one or more other ETS 
transcription factors. In another embodiment, the screening 30 
method includes the steps of (a) contacting a mithramycin 
derivative as a test agent or a test agent other than mith-
ramycin with the target ETS transcription factor in the 
presence of an oligonucleotide substrate; (b) assessing the 
effect of the test agent on the activity of the target ETS 35 
transcription factor; and (c) selecting test agents that exhibit 
specificity for and modulate the activity of the ETS tran-
scription factor relative to a reference or control sample or 
one or more other ETS transcription factors. 
In another embodiment relating to this aspect, the target 40 
ETS transcription factor is Friend leukemia integration 1 
transcription factor (FLil) or v-ets avian erythroblastosis 
virus E26 oncogene-like transcription factor (ERG). In 
another related embodiment relating to this aspect, the 
specificity of the test agent for the target ETS transcription 45 
is assessed by detecting the formation and/or stability of a 
complex formed between the transcription factor and its 
oligonucleotide substrate in the presence of the test agent 
relative to a reference or control sample or one or more other 
ETS transcription factors. In another related embodiment, 50 
the effect of the test agent on the activity the transcription 
factor is assessed by detecting the formation and/or stability 
of a complex formed between the transcription factor and 
the oligonucleotide substrate in the presence of the test agent 
relative to a reference or control sample. In another related 55 
embodiment, the activity of the test agent is assessed by 
measuring the effect of the test compound on the affinity of 
the transcription factor for the oligonucleotide substrate. In 
another related embodiment, step (b) discussed above fur-
ther includes assessing the formation of a complex compris- 60 
ing the MTM SA derivative, the target ETS transcription 
factor and the oligonucleotide substrate. 
In another aspect, the subject technology provides a 
method for modulating the activity of a target erythroblast 
transformation-specific (ETS) transcription factor in a 65 
patient in need thereof, including administering to the 
patient a therapeutically effective amount of an MTM SA 
4 
derivative or a pharmaceutically acceptable salt thereof 
having the following formula: 
or a pharmaceutically acceptable salt thereof; wherein Z and 
R represent the same groups as described herein, including 
all of the various embodiments thereof. 
In another aspect, the subject technology provides a 
method of treating a target ETS transcription factor-medi-
ated disease in a patient by administering to the patient a 
therapeutically effective amount of an MTM SA-Phe, MTM 
SA-Trp or any other MTM SA derivative described herein, 
wherein the MTM SA derivative specifically modulates the 
activity of the ETS transcription factor mediating the disease 
and wherein the target ETS-mediated disease is Ewing 
sarcoma, clear-cell sarcoma, myxoid liposarcoma, desmo-
plastic small round cell tumor, myxoid chondrosarcoma, 
acute myeloid leukemia, congenital fibrosarcoma, prostate 
cancer or pancreatic cancer. In an embodiment of this aspect, 
the target ETS transcription factor specifically modulated is 
Friend leukemia integration 1 transcription factor (FLil) or 
v-ets avian erythroblastosis virus E26 oncogene-like tran-
scription factor (ERG). 
In another aspect, the subject technology provides an 
isolated non-naturally-occurring mutant or engineered ETS 
transcription factor that comprises a DNA binding domain 
having the sequences of SEQ ID N0:01 or SEQ ID N0:02, 
wherein the transcription factor includes at least one amino 
acid substitution at any of amino acid residues correspond-
ing to residues Tyr68, Lys75, His77, Gly78, Lys79, Arg80, 
Tyr81, Ala82 of SEQ ID NO:Ol or SEQ ID N0:02. In an 
embodiment relating to this aspect, the engineered ETS 
transcription factor comprises a DNA binding domain that is 
at least 85% identical to SEQ ID NO:Ol or SEQ ID N0:02 
over the entire length of either of these sequences. In another 
related embodiment the engineered ETS transcription factor 
is Friend leukemia integration 1 transcription factor (FLil) 
or v-ets avian erythroblastosis virus E26 oncogene-like 
transcription factor (ERG). In another related embodiment, 
the engineered ETS transcription factor has a substantially 
similar, increased, or decreased DNA binding activity rela-
tive to the DNA binding activity of a wild-type ETS tran-
scription factor. 
Additional advantages of the present invention will 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 
embodiment of the invention is shown and described, simply 
by way of illustration of the best mode contemplated of 
carrying out the invention. As will be realized, the invention 
is capable of other and different embodiments, and its 
several details are capable of modifications in various obvi-
ous respects, all without departing from the invention. 
Accordingly, the drawings and description are to be regarded 
as illustrative in nature, and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Reference is made to the attached drawings, wherein 
elements having the same reference numeral designations 
represent similar elements throughout and wherein: 
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FIG. 1 is a schematic representation of the accumulation 
ofMTM SK, MTM SDK, and MTM SA by the inactivation 
of the mtm W gene in the MTM biosynthetic pathway. 
FIG. 2 illustrates two ways to produce the starting mate-
rial MTM SA and also shows various MTM SA derivatives. 5 
FIG. 3 illustrated functionalization of MTM SA through 
a reaction with a primary amine containing compound. 
Representative compounds are shown. 
FIG. 4 illustrates five exemplary MTM SA derivatives 
that exhibit high specificity for EWS-FLI1 transcription 10 
factor in Ewing sarcoma. 
FIG. 5 illustrates certain MTM SA derivatives including 
substituted MTM SA-Trp and MTM SA-Phe. 
FIG. 6 shows the amino acid sequence (SEQ ID NO: 7) 
of FLI1 transcription factor, with the DNA binding domain 15 
in that sequence highlighted. 
FIG. 7 shows the amino acid sequence (SEQ ID NO: 8) 
of ERG transcription factor, with the DNA binding domain 
in that sequence highlighted. 
FIG. 8 shows a comparison between the amino acid 20 
sequences of the DNA binding domains of FLil (SEQ ID 
NO:Ol) and ERG (SEQ ID N0:02), with the MTM inter-
acting residues underlined. 
FIG. 9 illustrates the average absolute (left) and relative 
(right) cytotoxicity (to cell proliferation) of MTM and its 25 
analogues against Ewing sarcoma (EWS) relative to non-
Ewing sarcoma cell lines. 
FIG. 10 shows the potency and specificity of MTM 
SA-Phe in killing of Ewing sarcoma cells. 
FIG. llA, FIG. llB, FIGS. llC, llD, and llE provide a 30 
series of graphs showing that MTM analogs have increased 
cytoxicity and distinct cell cycle distribution in Ewing 
sarcoma. The graphs show relative gene expression in TC32 
cells treated with MTM analogs. Three genes controlled by 
the EWS-FLil transcription factor were investigated by 35 
qRT-PCR at four different treatment concentrations for 6 
hours. CCK served as a negative control. 
FIG. 12(a) shows the 72-hour cytotoxicity results in 
TC32, 5838, SK-ES-1, RD-ES, TC71, RH-30, A673, ES-2, 
ES-3, ES-4, ES-7, ES-8 Ewing sarcoma cell lines (o EWS) 40 
and A549, PC3, DU145, OVCAR-8, C42, VCap, LNCap, 
U118 non-Ewing sarcoma cell lines (DNon-EWS). FIG. 
12(b) is a FACs analysis ofTC32 cells treated with 100 nM 
of drug for 24 hours. 
6 
function of EWS-FLI1 required for oncogenesis and tumor 
progression. The inventors have identified certain MTM SA 
derivatives including MTM SA-Phe and MTM SA-Trp that 
exhibit greater selectivity for EWS-FLil transcription factor 
and against Ewing's sarcoma cells than MTM itself. 
The systematic investigations of the DNA interaction of 
certain of these lead drugs led to discovery of the mechanism 
of action of MTM, which not only explains all effects of 
MTM observed thus far, but now serves as the basis for 
further systematic improvement and fine-tuning of the lead 
analogues. Briefly, the inventors have found that MTM 
increases the binding affinity of EWS-FLI1 to promoter 
DNA both by DNA remodeling and through specific direct 
MTM-EWS-FLil interactions, i.e., locks a ternary drug-
DNA-transcription factor complex. This mechanism is fun-
damentally different from the generally accepted mechanism 
of action of MTM (displacement of Sp-type transcription 
factors from the DNA promoter region by MTM), which can 
account for the general toxicity of MTM, but caunot explain 
its potent and selective antagonism of EWS-FLil. The 
discovery of a direct interaction between MTM, bound in the 
minor groove of the DNA, and the transcription factor 
EWS-FLI1, bound in the nearby major groove, was utilized 
to generate optimized MTM analogues with increased speci-
ficity for a target transcription factor. 
In the following detailed description, numerous specific 
details are set forth to provide a full understanding of the 
subject technology. It will be apparent, however, to one of 
ordinarily skilled in the art that the subject technology may 
be practiced without some of these specific details. In other 
instances, well-known structures and techniques have not 
been shown in detail so as not to obscure the subject 
technology. 
All references cited herein are incorporated by reference 
in their entirety as though fully set forth. Unless defined 
otherwise, technical and scientific terms used herein have 
the same meaning as commonly understood by one of 
ordinary skill in the art to which subject technology belongs. 
DEFINITIONS 
To facilitate an understanding of the present subject 
technology, a number of terms and phrases are defined 
below: 
45 A reference to an element in the singular is not intended 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
The MTM SA derivatives disclosed herein are examples 
of modified natural products that exhibit improved antican-
ceractivity in comparision to the natural product. It is 
believed that MTM acts by cross-linking GC-rich DNA 
thereby shutting down the transcription of several proto-
oncogenes, particularly pathways regulated by transcription 
factors Sp1 and Sp3. The Sp1 transcription factors are 
important as they have been linked to the control of cell 
growth, survival, and differentiation and their overexpres-
sion has been observed in several cancers. 
Extensive combinatorial biosynthesis has been performed 
on the drug biosynthesis pathway to produce altered MTM 
analogues for the purpose of improving their toxicity pro-
files. This has resulted in several novel useful compounds 
for the treatment of Ewing sarcoma and other cancers. 
The inventors have discovered inter alia that MTM SA 
binds DNA substrate together and cooperatively with EWS-
FLil, resulting in a ternary MTM SA: DNA substrate:EWS-
FLil complex, which, in turn, perturbs the transcription 
to mean "one and only one" unless specifically stated, but 
rather "one or more." 
As used herein, a "target ETS transcription factor" refers 
to a transcription factor which comprises a DNA-binding 
50 domain (DBD) having an amino acid sequence that is at least 
85% identical to SEQ ID N0:01 or SEQ ID N0:02 over the 
entire length of either of these sequences. SEQ ID NO:Ol 
and SEQ ID N0:02 are provided in FIG. 8. 
As used herein the term "modulator," "modulating," or 
55 "modulate" in connection with the target ETS transcription 
factor of the subject technology refers to any agent that has 
a functional effect on the transcription factor, including 
positively or negatively affecting its binding to a DNA 
substrate, positively or negatively affecting the formation 
60 and/or stability of a complex formed between the transcrip-
tion factor and its oligonucleotide substrate, positively or 
negatively affecting its function in causing the transcription 
of its oligonucleotide substrate. 
As used herein, the term "vector" is a composition of 
65 matter which comprises an isolated nucleic acid and which 
can be used to deliver the isolated nucleic acid to the interior 
of a cell. Numerous vectors are known in the art including, 
US 9,447,135 B2 
7 
but not limited to, linear polynucleotides, polynucleotides 
associated with ionic or amphiphilic compounds, plasmids, 
and viruses. Thus, the term "vector" includes an autono-
mously replicating plasmid or a virus. The term should also 
be construed to include non-plasmid and non-viral com- 5 
pounds which facilitate transfer of nucleic acid into cells, 
such as, for example, poly lysine compounds, liposomes, and 
the like. Examples of viral vectors include, but are not 
limited to, adenoviral vectors, adena-associated virus vec-
tors, retroviral vectors, and the like. 
The term "variant" in relation to the amino acid sequence 10 
of the ETS transcription factors refers to a naturally occur-
ring allelic variant of the ETS transcription factors such as 
those shown in SEQ ID N0:07 and SEQ ID N0:08, which 
includes any substitution of, variation of, modification of, 
replacement of, deletion of or addition of one (or more) 15 
amino acids provided the resultant ETS transcription factor 
has a transcription factor activity and has a DNA binding 
domain that is at least 85% identical to SEQ ID N0:01 or 
SEQ ID N0:02 over the entire length of either of these 
sequences. For example, a variant of ETS transcription 20 
factor may have at least 50%, or at least 60%, or at least 70% 
sequence identity with the ETS transcription factors such as 
those shown in SEQ ID N0:07 and SEQ ID N0:08 over the 
entire length of the sequence, provided that the variant has 
~o!~f~c{~~ii~natff~~~{ 8~~:~!~yle=~d9g;:, a~ 1~~~5~n~!~~ 25 
least 98% identical to SEQ ID NO:Ol or SEQ ID N0:02 
over the entire length of either of these sequences. 
The terms "percentage of sequence identity" or "percent-
age homology" and any equivalent terms are used inter-
changeably herein to refer to comparisons among polynucle- 30 
otides and polypeptides, and are determined by comparing 
two optimally aligned sequences over a comparison win-
dow, wherein the portion of the oligonucleotide or polypep-
tide sequence in the comparison window may comprise 
additions or deletions (i.e., gaps) as compared to the refer- 35 
ence sequence (which does not comprise additions or dele-
tions) for optimal alignment of the two sequences. The 
percentage is calculated by determining the number of 
positions at which the identical nucleic acid base or amino 
acid residue occurs in both sequences to yield the number of 
matched positions, dividing the number of matched posi- 40 
tions by the total number of positions in the window of 
comparison and multiplying the result by 100 to yield the 
percentage of sequence identity. Identity is evaluated using 
any of the variety of sequence comparison algorithms and 
programs known in the art. Such algorithms and programs 45 
include, but are by no means limited to, TBLASTN, 
BLASTP, PASTA, TFASTA, CLUSTALW, FASTDB [Pear-
son and Lipman, (1988), Proc. Nat!. Acad. Sci. USA 85(8): 
2444-2448; Altschul eta!., (1990), J. Mol. Bioi. 215(3):403-
410; Thompson et a!. (1994), Nucleic Acids. Res. 22(2): 
8 
4673-4680; Higgins eta!., (1996), Meth. Enzymol. 266:383-
402; Altschul et a!., (1993), Nature Genetics 3:266-272; 
Brutlag et a!. (1990) Camp. App. Biosci. 6:237-24], the 
disclosures of which are incorporated by reference in their 
entireties. In an embodiment, protein and nucleic acid 
sequence identities are evaluated using the Basic Local 
Alignment Search Tool ("BLAST") which is well known in 
the art [e.g., Karlin and Altschul, (1990), Proc. Nat!. Acad. 
Sci. USA 87:2267-2268; Altschul eta!., (1997), Nuc. Acids 
Res. 25:3389-3402] the disclosures of which are incorpo-
rated by reference in their entireties. 
As used herein, an "oligonucleotide substrate" in refer-
ence to a substrate of a target ETS transcription factor refers 
to an oligonucleotide which comprises a target ETS tran-
scription factor binding site. An oligonucleotide substrate 
can be single-stranded, double-stranded, or a hairpin. Pref-
erably, an oligonucleotide substrate is double stranded. An 
oligonucleotide substrate can be DNA, RNA or a chimeric 
(comprising both deoxy and ribose nucleotides) or comprise 
one or more oligonucleotide modifications described herein. 
As used herein, the term "transcription factor binding 
site" refers to a nucleic acid sequence that is recognized and 
bound by a transcription factor and mediates the transacti-
vation of a reporter gene in response to that binding. Without 
limitations, a transcription binding site can be from any of 
various species including human, mouse, rat, guinea pig and 
the like. In some embodiments, the transcription factor 
binding site is a target ETS binding site such as a FLil 
binding site or an ERG binding site. 
The MTM SA derivatives of the subject technology can 
be synthesized according to the methods described below. 
The inactivation of the mtm W gene, which is the gene 
encoding the last acting enzyme in the MTM biosynthetic 
pathway, produced MTM analogues with a short side chain 
ketone (SK) and MTM with a short side chain diketone 
(SDK) (FIG. 1). Both of these analogues possess shorter side 
chains at the 3-position. The 3-side chain has been identified 
previously as important, since it is in part responsible for 
MTM's interaction with the DNA phosphate backbone. See 
U.S. Pat. No. 7,423,008. Both MTM SK and MTM SDK 
showed increased activity against several cancer cell lines 
compared to the parent MTM. These results indicate that the 
3-side chain is important for the activity of MTM and offers 
a base for further molecular manipulations. As an unwanted 
side product along with the production of the desired MTM 
SK and MTM SDK analogues, MTM side chain carboxylic 
acid (SA) is also accumulated in the Mtm W-minus-mutant, 
but showed in contrast to MTM SK and MTM SDK sig-
nificantly decreased activity compared to MTM. 
MTA SA is shown in formula (I) below: 
(I) 
CH3 CH3 
HO~QHO~Q 0 HO~O~ OH 
0 
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thesis. ChemBioChem 2008, 9 (14), 2295-2304; (c) Nunez, 
L. E.; Nybo, S. E.; Gonzalez-Sabin, J.; Perez, M.; Menen-
dez, N.; Braiia, A. F.; He, M.; Moris, F.; Salas, J. A.; Rohr, 
J.; Mendez, C., A Novel Mithramycin Analogue with High 
Antitumor Activity and Less Toxicity Generated by Com-
binatorial Biosynthesis. J. Med. Chern. 2012, 55, 5813-
5825; (d) Remsing, L. L.; Garcia-Bernardo, J.; Gonzalez, A. 
M.; Kunze!, E.; Rix, U.; Braiia, A. F.; Bearden, D. W.; 
Mendez, C.; Salas, J. A.; Rohr, J., Ketopremithramycins and 
One reason for MTM-SA's decreased activity might be 
that its 3-side chain is too short and its negatively charged 
carboxylic acid does not sufficiently interact with naturally 
negatively charged DNA. To overcome these potential defi-
ciencies, a semi-synthetic approach was used herein to 
chemically modifY the unique carboxylic acid moiety of 
MTM SA to introduce new functionalities into the 3-side 
chain. In one aspect of the present disclosure, the MTM SA 
derivatives have the following formula: 
II 
10 ketomithramycins, four new aureolic acid-type compounds 
obtained upon inactivation of two genes involved in the 
biosynthesis of the deoxysugar moieties of the antitumor 
drug mithramycin by Streptomyces argillaceus, reveal novel 
insights into post-PKS tailoring steps of the mithramycin 
15 biosynthetic pathway. J. Am. Chern. Soc. 2002, 124 (8), 
1606-1614; (e) Remsing, L. L.; Bahadori, H. R.; Carbone, 
G. M.; McGuffie, E. M.; Catapano, C. V.; Rohr, J., Inhibition 
of c-src transcription by mithramycin: structure-activity 
relationships ofbiosynthetically produced mithramycin ana-
where Z represents 0, S, N-R'; R and R' represent, for 
each occurrence, H, alkyl, e.g., lower straight chain or 
branched alkyl, heterocyclic, aryl, e.g., phenyl, naphthyl, 
heteroaryl, e.g., pyridyl, pyrolidyl, piperidyl, pyrimidyl, 
indolyl, thienyl, provided that R is not H when Z is 0; ZR 
taken together represents an organic residue, e.g., an alkyl, 
e.g., lower straight chain or branched alkyl, heterocyclic, 
aryl, e.g., phenyl, naphthyl, heteroaryl, e.g., pyridyl, 
pyrolidyl, piperidyl, pyrimidyl, indolyl, thienyl, an amino 
acid conjugate or its ester derivative, e.g., proline (Pro), 
alanine (Ala), serine (Ser), cysteine (Cys), histidine (His), 
tryptophan (Trp ), tyrosine (Tyr), phenylalanine (Phe) con-
jugate, etc., a sugar or sugar chain. Each of the alkyl, 
heterocyclic, aryl, heteroaryl, sugar, or sugar chain of R, R' 
and ZR can be unsubstituted or substituted with one or more 
amino, alkyl amino, alkylcarboxyl, alkoxyl, alkylcarbonyl, 
hydroxyl, thio, alkyldisulfide, heterocyclic, aryl, heteroaryl, 
halo, e.g., fluoro, chloro, bromo, iodo, an amino acid con-
jugate, ether, ester, amide residue, etc. The group MTM1 
represents the fused ring portion of the mithramycin struc-
ture and can include different sugars or sugar chains. In other 40 
words, MTM1 represents the structure of formula III below, 
but also variants with different sugar patterns. 
CH3 CH3 
Ho~QHo~Q 0 HO~O~ 6 B A 
20 logues using the c-src promoter as target. Biochemistry 
2003, 42 (27), 8313-8324. Pharmaceutically acceptable salts 
of the MTM SA derivative are also contemplated by the 
present disclosure. 
Preferably, Z represents NH, 0, or S and R represents 
25 alkyl, aryl, heterocyclic, heteroaryl, etc., and when ZR is 
taken together, ZR represents an amino acid conjugate or its 
ester (e.g., a methyl ester). In certain embodiments, the 
MTM SA derivative is an amide derivative, e.g. ZR together 
form a NR1 R2 group where R1 and R2 can be the same or 
30 different and each of R1 and R2 can be an H, alkyl, or an 
amino acid conjugate or an ester derivative thereof. In other 
embodiments, the MTM SA derivative is an amino acid 
derivative, e.g. NR1 R2 together form an amino acid conju-
gate or an ester derivative thereof which can be further 
35 substituted. 
Previous work by Preobrazhenskaya et a!. (References 
numbered 26-28) on olivomycin derivatizations showed that 
introduction of N-atoms can improve aureolic acid type 
anticancer drugs. The inventors discovered that MTM SA 
derivatives with N -atoms can have improved efficacy. In one 
embodiment of the present disclosure, MTM SA is deriva-
tized with an amine to form an amide. Such MTM SA amide 
derivatives advantageously have an elongated 3-side chain 
and one or more N-atom/s, which can enhance the interac-
III 45 tion of the derivative with the DNA-phosphate backbone 
resulting in improved efficacy. In one aspect of the present 
disclosure, the MTM SA derivative is provided by formula 
(IV) below: 
50 
55 
C)yH30 /RI 
N'-. 
MTM1 R2 
0 
IV 
Thus, the A, B, C, D, E, sugars can be different from those 
shown, and include chain variants. Such sugars are dis-
closed, for example, in: (a) Baig, I.; Perez, M.; Braiia, A. F.; 60 
Gomathinayagam, R.; Damodaran, C.; Salas, J. A.; Mendez, 
where R1 and R2 can be the same or different and each ofR1 
and R2 can be an H, an amino acid conjugate or ester thereof, 
a lower straight chain or branched alkyl unsubstituted or 
substituted with one or more amino, alkyl amino, alkylcar-
boxyl, alkoxyl, alkylcarbonyl, hydroxyl, thio, alkyldisulfide, 
halo, e.g., fluoro, chloro, bromo, iodo, provided that R1 and 
R2 are not both H simultaneously. The amino acid conjugate 
and ester derivatives that can be included in formula (V), 
e.g., where NR1R2 form an amino acid conjugate or ester 
derivative thereof, include, for example, a proline (Pro, or 
C.; Rohr, J., Mithramycin analogues generated by combi-
natorial biosynthesis show improved bioactivity. J. Nat. 
Prod. 2008, 71 (2), 199-207; (b) Perez, M.; Baig, I.; Braiia, 
A. F.; Salas, J. A.; Rohr, J.; Mendez, C., Generation of new 65 
derivatives of the antitumor antibiotic mithramycin by alter-
ing the glycosylation pattern through combinatorial biosyn-
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0-alkyl-Pro ), alanine (Ala, or 0-alkyl-Ala), serine (Ser, or 
0-alkyl-Ser), cysteine (Cys, or 0-alkyl-Cys), histidine (His, 
12 
also neuroprotective and the MTM SA derivative can be 
used to treat various neuro-diseases, such as Huntington 
disease, etc. 
The biosynthesis ofMTM SK and MTM SDK is accom-
plished through a genetically engineered S. argillaceus 
strain, M7Wl, which contains an inactivated mtm W gene 
coding for the Mtm W enzyme. Both the MTM SK and MTM 
SDK analogues have improved activity compared to the 
parent MTM compound, thus it would be optimal if these 
were the only two compounds produced by the M7Wl 
strain. However, this is not the case, and two other major 
compounds are produced alongside of MTM SK and MTM 
SDK. One of these compounds, MTM SA, has previously 
been disregarded as invaluable due to the relative lack of 
or 0-alkyl-His), tryptophan (Trp, or 0-alkyl-Trp), tyrosine 
(Tyr, or 0-alkyl-Tyr), and phenylalanine (Phe, or 0-alkyl-
Phe) conjugate. Further, the amino acid conjugate or its 5 
derivative can be substituted, e.g., substituted with -R3 Y 
where R3 is alkyl, e.g., C1 _16 or C1 _8 alkyl, andY is a formyl, 
ene, expoxy, aryl, e.g., phenyl, heteroaryl, e.g., indolyl, 
group. In some embodiments -R3 Y together form an 
allylox group. In some embodiments, the amino acid con- 10 
jugate is phenylalanine (e.g., MTM SA-Phe) or an ester 
derivative thereof or tryptophan (e.g., MTM SA-Trp) or its 
ester derivative. Each of the MTM SA-Trp and MTM 
SA-Phe and its ester derivatives can further be substituted, 
e.g., substituted with -R3 Y. 15 biological activity compared to the parent compound. This is 
unfortunate as MTM SA is produced in many fermentations 
in higher amounts than MTM SK or MTM SDK, and the 
production yield can be shifted even further in favor of the 
In one embodiment of the present disclosure, the MTM 
SA derivative is an amino acid derivative, i.e., at least one 
of R1 or R2 is an amino acid conjugate, e.g., proline (Pro), 
alanine (Ala), serine (Ser), cysteine (Cys), histidine (His), 
tryptophan (Trp ), tyrosine (Tyr), conjugate. Preferably R1 is 20 
an amino acid conjugate and R2 is H. For example, the MTM 
SA derivative can be a MTM SA 0-Me-tryptophan deriva-
tive as shown in formula V below: 
40 
FIG. 2 illustrates two different ways to produce the 
starting material MTM SA and also shows various MTM SA 
derivatives. In the figure, the MTM1 group can include 
different sugars or sugar chains, R represents a lower straight 
chain or branched alkyl unsubstituted or substituted with one 45 
or more amino, alkyl amino, alkylcarboxyl, alkoxyl, alkyl-
carbonyl, hydroxyl, thio, alkyldisulfide, halo other residues. 
production of MTM SA by altering the pH of the culture 
media. Since MTM SK and MTM SDK are separated 
chromatographically MTM SA is easily collected and iso-
lated alongside MTM SK and MTM SDK during the normal 
isolation procedure. 
H 
N 
0 
v 
An aspect of the present disclosure involves targeting the 
3-side chain of MTM SA to form useful MTM SA deriva-
tives. It is known that the 3-side chain of the MTM structure 
is responsible for an interaction with the DNA-phosphate 
backbone. Thus by altering the functionality of the 3-side 
chain the specificity for the DNA of diseased cells can be 
improved. The 3-side chain of MTM SA is terminated by a 
carboxyl acid functional group which is likely ionized at a 
physiological pH, repulsing from the negative charge of the 
DNA phosphate backbone thereby weakening MTM SA's 
ability to bind to the DNA. 
In addition, the NR1 R2 can form an amino acid conjugate or 
ester derivative thereof as shown in FIG. 2. In one aspect of 
the present disclosure, MTM SA amide derivatives can be 50 
prepared by coupling the terminal carboxylic acid group of 
MTM SA with an amine, e.g., a primary amine, to form the 
MTM SA derivative. 
In one aspect of the present disclosure, side chain func-
tionalizations were rationally selected to contain cationic 
amine residues in order to enhance the interaction with the 
55 DNA phosphate backbone. Examples of particular MTM SA derivatives together 
with their activity are provided in Table 2 in the Examples 
section below. Additionally, other amino acid derivatives of 
MTM SA can be prepared. For example, tryptophan can be 
substituted on the MTM SA derivative. The MTM SA-
tryptophan derivative can be prepared the same way as the 
other amino acid derivatives, only using Tryptophan-0-
methyl ester. OMe-Phe, OMe-Tyr and OMe-His derivatives 
can be prepared in the same manner. 
The MTM SA derivatives of the present disclosure can be 
used for the treatment of cancer, such as brain, colon, 
prostate, lung, breast, esophageal, pancreatic, skin, Ewing 
sarcoma, any type of blood cancer etc. MTM derivatives are 
Screening Methods 
The assay described herein provides a rational develop-
ment and identification scheme for novel and potent MTM 
analogues and derivatives with improved selectivity against 
60 EWS-FLil. Without wishing to be bound by a theory, the 
inventors have discovered inter alia that rather than displac-
ing EWS-FLil from DNA, MTM binds DNA cooperatively 
with EWS-FLil and hyperstabilizes it on the DNA (FIG. 4), 
to disruption of its transcriptional functions residues in order 
65 to enhance the interaction with DNA phosphate backbone. 
Accordingly, in one aspect the subject technology pro-
vides a screening assay for identifying MTM SA derivatives 
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complex; a sample containing a compound that may com-
pete with the test compound to complex with the target ETS 
transcription factor; or a sample exposed to an excess 
amount of a labeled or an unlabeled binding member of the 
complex. Methods of determining formation and/or stability 
of the complex are described below. 
as test compounds that selectively and specifically bind to 
and modulate the activity of a target ETS transcription factor 
such as EWS-FLI1 transcription factor. The assay includes 
such steps as detecting the formation and/or stability of a 
complex that includes (1) a target ETS transcription factor 
that has a DNA binding domain with an amino acid sequence 
that is at least 85% identical to SEQ ID N0:01 or SEQ ID 
N0:02 over the entire length of either of these sequences, (2) 
an oligonucleotide substrate and (3) the test compound. 
According to some embodiments, the interactions 
between a target ETS transcription factor, its oligonucleotide 
substrate and an MTM SA derivative is fine-tuned by proper 
10 
chemical modification of the MTM SA derivative to increase In some embodiments, the subject technology provides a 
method for screening mithramycin (MTM) derivatives 
including MTM SA or a pharmaceutically acceptable salt 
thereof for an ability to selectively complex with or modu-
late the activity of a target ETS transcription factor, said 
method including the steps of (a) contacting the MTM SA 15 
derivative with the target ETS transcription factor in the 
presence of an oligonucleotide substrate; (b) assessing the 
effect of the MTM SA derivative on the activity of the target 
ETS transcription factor; and (c) selecting the MTM SA 
derivative that has specificity for and/or modulates the 20 
activity of the target ETS transcription factor relative to a 
reference or control sample; wherein the target ETS tran-
scription factor is Friend leukemia integration 1 transcrip-
tion factor (FLil) or v-ets avian erythroblastosis virus E26 
oncogene-like transcription factor (ERG). In some related 25 
embodiments, the step (b) further includes assessing the 
formation of a complex comprising the MTM SA derivative, 
the target ETS transcription factor and the oligonucleotide 
substrate. In some related embodiments, the step of assess-
ing the formation of the complex is performed by crystal- 30 
lography. In some related embodiments, the specificity of 
the test agent for the target ETS transcription is assessed by 
detecting the formation and/or stability of a complex formed 
between the target ETS transcription factor and its oligo-
nucleotide substrate in the presence of the MTM SA deriva- 35 
tive relative to a reference or control sample. In some related 
embodiments, the specificity of the test agent for the target 
ETS transcription is assessed by detecting the formation 
and/or stability of a complex including the target ETS 
transcription factor, the oligonucleotide substrate and the 40 
MTM SA derivative. In some related embodiments, the 
oligonucleotide substrate includes SEQ ID NOs:03-07. In 
some related embodiments, the oligonucleotide substrate is 
labeled with a detectable label. In some related embodi-
ments, the MTM SA derivative or a pharmaceutically 
acceptable salt thereof is a compound described herein. 
MTM SA-Phe is an exemplary MTM SA derivative that 
selectively and specifically binds to a target ETS transcrip-
tion factor such as EWS-FLil is MTM SA-Phe which forms 
a ternary MTM SA-Phe:EWS-FLil:DNA substrate complex 
that hyperstabilizes the transcription factor to its binding 
site, thus, perturbing the normal function of the transcription 
factor. Another such example is MTM SA-Trp. 
According to some embodiments of the subject technol-
ogy, the amount or stability of the complex in the presence 
of a test compound such as an MTM SA derivative is 
determined relative to a control or reference sample. A 
statistically significant increase in stability is indicative of an 
increase in the formation of the complex or an increase in the 
specificity of the test compound for the transcription factor. 
A control or reference sample can be one or more of a 
sample not exposed to the test compound; a sample exposed 
to known inhibitor of the target ETS transcription factor 
(e.g., FLil or ERG); a sample containing one or more other 
ETS transcription factors capable competing with the target 
ETS transcription factor for forming a complex with the test 
compound; a sample exposed to a known inhibitor of the 
the specificity of the derivative for the target transcription 
factor. In some embodiments, the MTM SA derivative of the 
subject technology, while having high specificity for a target 
ETS transcription factor such as FLI1, will not displace the 
Sp transcription factors from the GC-rich promoter DNA. In 
the case of Ewing sarcoma, where the target ETS transcrip-
tion factor is EWS-FLil, the MTM SA derivative of the 
subject technology selectively complexes with and inhibits 
the activity of the EWS-FLil transcription factor and, thus, 
is a potent and selective anti-Ewing sarcoma therapy. 
A variety of assay formats can be used and, in light of the 
present disclosure, those not expressly described herein will 
nevertheless be understood to be included by one of ordinary 
skill in the art. Screening methods or assay formats which 
approximate such conditions as formation of a ternary 
complex of a target ETS transcription factor (e.g., FLI1 or 
ERG):oligonucleotide substrate:MTM SA derivative can be 
generated in many different forms, and include assays based 
on cell-free systems, e.g., purified peptides and oligonucle-
otides or cell lysates, as well as cell based assays which 
utilize intact cells and in vivo assays. 
The components of the complex can be added simulta-
neously to the assay sample, e.g., a reaction mixture or they 
can be added sequentially in any order, e.g., forming a 
mixture of the first component with a second component, 
adding the third component forming a mixture of the first, 
second, and third component, and adding the fourth com-
ponent. In some embodiments, some components of the 
complex are added sequentially while others are added 
simultaneously, e.g., forming a reaction mixture with a first 
component with a second component and adding the third 
and fourth component simultaneously to the mixture, or 
45 adding a first component followed by simultaneous addition, 
e.g., a reaction mixture, of the rest of the components. 
Assaying in the presence and absence of a test compound 
can be accomplished in any vessel suitable for containing 
the reactants. Examples include microtitre plates, test tubes, 
50 and micro centrifuge tubes. Alternatively, the sample can 
include cells in culture, e.g., purified cultured or recombi-
nant cells, or in vivo in an animal subject. 
In some embodiments, the screening assays can be per-
formed in vitro using isolated/purified complex components. 
55 In such a system, each component of the screen can be added 
separately in wells of a multi-well plate. In some embodi-
ments, the multimeric complex will be allowed to form prior 
to the addition of the test compound to be screened. In other 
embodiments, the members of the complex and the test 
60 agent will be added together, e.g., at the same time or 
simultaneously, with one or more of the members of the 
complex. 
Complex components can be used at any concentration 
suitable for the assay conditions being used, e.g., size of the 
65 reaction vessel, time limitations, detection limits, amount of 
the limiting component, etc. Additionally, amount of the 
various components of the complex can be the same, all 
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different, or combinations thereof. Generally, amount of 
each component is within 15% to 5% of the amount of each 
of the other components. 
In some embodiments, the concentration of each of the 
complex components in the assay sample is independently 
from about 0.01 nM to about 1.0 mM. In some embodi-
ments, the concentration of each of the complex components 
is independently from about 0.1 nM to about 100 f.LM, from 
about 0.5 nM to about 50 f.LM, or from about 1 nM to about 
16 
3x, at least 4x, at least 5x or more relative to the amount of 
another complex component. In some embodiments, the 
competitor is present in an amount which is at least 0.1x, at 
least 0.2x, at least 0.3x, at least 0.4x, at least 0.5x, at least 
0.6x, at least 0.7x, at least O.Sx, at least 0.9x, at least 1 x, at 
least 1.25x, at least 1.5x, at least 1.75x, at least 2x, at least 
2.5x, at least 3x, at least 4x, at least 5x or more relative to 
the amount of the complex component being competed 
against. 
25 f.LM. In some embodiments, the concentration of each of 10 
the complex component is independently from about 10 nM 
Any suitable buffer/media/solvent can be used in the 
screening assay. Exemplary buffers include, but are not 
limited to, phosphate buffered saline (PBS), sodium phos-
phate, sodium sulphate, Tris buffers, Tris-HCl buffers, gly-
cine buffer, and sterile water. The buffer can be present in the 
to about 40 f.LM. In one embodiment, the concentration of 
each of the complex components is about 10 nM, or about 
20 nM, or about 50 nM, or about 100 nM, or about 250 nM, 
or about 1 f.LM. In one embodiment, concentration of each of 
the complex component is greater than 20 nM. 
The assay sample volume depends on the particular setup 
being used for the screening assay. Generally, the assay 
sample has a final volume of about 10 nl to about 1 mi. In 
some embodiments, the final volume of the sample assay is 
from about 1 ml to about 100 mi. In addition to the complex 
components, a variety of other reagents can be included in 
the screening assay samples. These include reagents like 
salts, neutral proteins, e.g., albumin, detergents, etc. that are 
used to facilitate optimal protein-protein binding and/or 
reduce nonspecific or background interactions. Reagents 
that improve the efficiency of the assay, such as protease 
inhibitors, single stranded nuclease inhibitors, anti-micro-
bial compounds are also included. The mixture of compo-
nents is added in any order that provides for the requisite 
assembly of the complex. 
In some embodiments, the assay sample comprises a 
competitor of at least one component of the complex. The 
term "competitor of a component of the complex" refers to 
a compound or composition that competes with said com-
ponent for binding with another component of the complex. 
For example, an unlabeled complex component can be 
considered a competitor of the labeled component. In 
another example, an oligonucleotide comprising either a 
target ETS transcription factor binding site or a transcription 
binding site is a competitor of the oligonucleotide substrate 
of the target ETS transcription factor. In some embodiments, 
the competitor is another ETS transcription factor other 
than, for example, a FLI1 or ERG. In another embodiment, 
the competitor is an MTM SA derivative other than the one 
being assayed. 
The amount of a competitor of a component of the 
complex in the sample assay can be adjusted to optimize the 
detection of the assay. Accordingly, in some embodiments, 
concentration of the competitor in the assay sample is from 
about 0.01 nM to about 1000 nM. In some embodiments, 
amount of the competitor in the assay sample is from about 
0.1 nMto about 100 f.LM, from about 0.5 nMto about 50 f.LM, 
or from about 1 nM to about 25 f.LM. In some embodiments, 
amount of the competitor in the assay sample is from about 
10 nM to about 20 f.LM. In some embodiments, amount of the 
competitor in the assay sample is from about 150 nM to 
about 250 nM. In one embodiment, concentration of the 
competitor in the assay sample is about 10 nM, about 20 nM, 
or about 200 nM. 
The amount of a competitor of a component of the 
complex in the sample assay can be relative to any other 
component of the complex. For example, the competitor can 
be present in an amount which is at least 0.1x, at least 0.2x, 
15 assay sample at any suitable concentration. Typically, the 
assay sample comprises a buffer in a concentration of about 
5-100 mM. In some embodiments, the assay sample com-
prises a buffer in a concentration of about 5-75 mM (e.g., 10 
mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, or 
20 50 mM). Generally, the buffer has a pH of from about 5 to 
about 10. In some embodiments, the buffer has a pH of from 
about 6 to about, from about 6.5 to about 8, or from 6.5 to 
about 7.5. The pH of the buffer can be adjusted by addition 
of any suitable acid or base (e.g., HCl). In some embodi-
25 ments, the sample buffer is 20 mM Tris pH 7.5, 50 mM 
NaCl, 5% glycerol, 0.5 mg/ml BSA. 
Formation and/or stability of the complex can be assayed 
at any suitable temperature. Accordingly, in some embodi-
ments, the formation and/or stability of the complex is 
30 assayed at a temperature in the range of about 15° C. to 
about 65° C. In some embodiments, the formation and/or 
stability of the complex is assayed at a temperature in the 
range of about 15° C. to about 45° C. In some embodiments, 
the formation and/or stability of the complex is assayed at a 
35 temperature in the range of about 15° C. to about 25° C. 
After all of the reagents have been added, evaluation of 
the complex formation or stability can be done right away, 
e.g., within 5 minutes of addition of last reagent, or after a 
period of time has elapsed after addition of the last reagent. 
40 In some embodiments, the sample assay is allowed to 
incubate for at least 5 minutes, at least 10 minutes, at least 
15 minutes, at least 20 minutes, at least 25 minutes, at least 
30 minutes, at least 35 minutes, at least 40 minutes, at least 
45 minutes, at least 1 hour, at least 2 hours, at least 5 hours 
45 or more before evaluating the complex formation or stabil-
ity. In one embodiment, the assay sample is allowed to 
incubate for 30 minutes after addition of the last reagent 
before evaluating the complex formation or stability. 
The assays of the subject technology can be used to 
so evaluate and/or detect a change in complex formation and/or 
complex stability by detecting one or more of (1) a change 
in the binding or physical formation of the complex itself, 
e.g., by biochemical detection, affinity based detection (e.g., 
Western blot, affinity columns), immunoprecipitation, fluo-
55 rescence resonance energy transfer (FRET)-based assays 
(e.g., FRET or Time Resolved FRET (TR-FRET) assays), 
surface plasmon resonance (SPR), spectrophotometric 
means (e.g., circular dichroism, absorbance, and other mea-
surements of solution properties); (2) an increase or a 
60 decrease, in signal transduction, e.g., phosphorylation and/or 
transcriptional activity; (3) an increase or decrease in cell 
function. All of these methods are known in the art. 
at least 0.3x, at least 0.4x, at least 0.5x, at least 0.6x, at least 65 
0.7x, at least O.Sx, at least 0.9x, at least 1 x, at least 1.25x, 
In some embodiments, the screening assay is a high-
throughput screening assay. HTS is a relative term, but is 
generally defined as the testing of 10,000 to 100,000 com-
pounds per day, accomplished with mechanization that 
at least 1.5x, at least 1.75x, at least 2x, at least 2.5x, at least ranges from manually operated workstations to fully auto-
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mated robotic systems using robotics, data processing and 
control software, liquid handling devices, and sensitive 
detectors. 
Methods of Treatment 
18 
In one aspect, the subject technology provides a method 
for selectively modulating the activity of a target ETS 
transcription factor in a patient in need thereof, including 
administering to the patient a therapeutically effective 
amount of an MTM SA derivative or a pharmaceutically 
acceptable salt thereof having the following formula: 
In other embodiments relating to this aspect, the MTM SA 
derivative is MTM SA-Phe or MTM SA-Trp and the target 
ETS transcription factor being selectively modulated is FLI 1 
and/or ERG. In other embodiments relating to this aspect, 
the MTM SA derivative is MTM SA-Phe or MTM SA-Trp 
which further include one or more different sugar groups 
such as D-digitoxose and the target ETS transcription factor 
being modulated is FLil and/or ERG. In other embodi-
ments, administration results in modulation of the activity of 
10 the ETS transcription factor in the patient. In other embodi-
ments, the target ETS transcription factor is Friend leukemia 
integration 1 transcription factor (FLil) or v-ets avian 
erythroblastosis virus E26 oncogene like transcription factor 
15 (ERG). 
In another aspect, the subject technology provides a 
method of treating a target ETS transcription factor-medi-
ated disease in a patient by administering to the patient a 
therapeutically effective amount of an MTM SA-Phe, MTM 
wherein Z represents 0, S, N-R'; R and R' represent, for 
each occurrence, H, alkyl, heterocyclic, aryl, heteroaryl, 
provided that R is not H when Z is 0; ZR taken together 
represents an organic residue; and wherein MTM1 represents 
the fused ring portion of the mithramycin structure and can 
include different sugars or sugar chains. In addition, Z and 
R can represent all of the various embodiments described 
herein including when ZR together form an amide, amino 
acid conjugate or ester derivative thereof, etc. 
20 SA-Trp or any other MTM SA derivative described herein, 
wherein the MTM SA derivative specifically modulates the 
activity of the ETS transcription factor mediating the disease 
and wherein the target ETS-mediated disease is Ewing 
sarcoma, clear-cell sarcoma, myxoid liposarcoma, desmo-
In an embodiment relating to this aspect, the subject 
technology provides a method for selectively modulating the 
activity of a target ETS transcription factor in a patient with 
Ewing sarcoma or prostate cancer for example. The method 
includes administering to the patient a therapeutically effec-
tive amount ofMTM SA-Phe or MTM SA-Trp, or a deriva-
tive thereof, for example. In some embodiments relating to 
this aspect, the ETS transcription factor includes a DNA 
binding domain with an amino acid sequence that is at least 
85% identical to SEQ ID NO:Ol or SEQ ID N0:02 over the 
entire length of either of these sequences. In other embodi-
ments relating to this aspect, ZR together represents an 
NR1 R2 group, e.g., an amino acid conjugate or an ester 
derivative thereof. In certain embodiments, NR1 R2 is the 
amino acid conjugate is an aromatic amino acid conjugate, 
e.g., phenylalanine, tryptophan or an ester derivative 
thereof. The amino acid conjugate or ester derivative thereof 
can further be substituted. Substituents include, for example, 
-R3 Y where R3 is alkyl, e.g., C1_16 or C1 _8 alkyl, andY is 
25 plastic small round cell tumor, myxoid chondrosarcoma, 
acute myeloid leukemia, congenital fibrosarcoma, prostate 
cancer or pancreatic cancer, for example. Table 1 below lists 
several ETS transcription factors that may be modulated and 
associated diseases that may be treated with the subject 
30 technology. 
TABLE 1 
ETS Transcription factors and associated diseases. 
35 Transcription factor Disease 
40 
45 
50 
a formyl ene, expoxy, aryl, e.g., phenyl, heteroaryl, e.g., 
indolyl. In some embodiments -R3 Y together form an 
allylox group. In other embodiments relating to this aspect, 
the MTM SA derivative includes one or more sugar groups 
such as D-digitoxose. In other embodiments relating to this 
aspect, the MTM SA derivative is MTM SA-Phe or MTM 
SA-Trp and the target ETS transcription factor being selec-
tively modulated is FLil and/or ERG. In other embodiments 55 
relating to this aspect, the MTM SA derivative is MTM 
SA-Phe which further includes one or more different sugar 
groups such as D-digitoxose and/or an indole ring on the 
phenylalanine and the target ETS transcription factor being 
modulated is FLil and/or ERG. In other embodiments, the 60 
MTM SA derivative is MTM SA-Phe-Allylox and the target 
ETS transcription factor being selectively modulated is FLI 1 
and/or ERG. In other embodiments relating to this aspect, 
the MTM SA derivative is MTM SA-Phe-Allylox which 
further includes one or more different sugar groups such as 65 
D-digitoxose and the target ETS transcription factor being 
modulated is FLil and/or ERG. 
ETS-1 
ETS-2 
ERG 
FLil 
PEA3 
ER81 
ELF-1 
TELIETV6 
PU.1/SPI1 
Myc 
Meningioma, invasive carcinoma of the breast, 
colorectal carcinoma, pancreatic carcinoma, 
adenocarcinoma, thyroid carcinoma, thymoma, 
angioma 
Breast cancer 
TMPRSS2:ERG fusion in prostate cancer 
EWS-ERG fusion in Ewing Sarcoma 
ERG overexpression in AML 
EWS-FLil fusion in Ewing Sarcoma 
Invasive breast carcinoma 
EWS-ER81 fusion in Ewing sarcoma, prostate 
carcinoma, breast carcinoma 
Prostate, ovarian and breast cancers, leukemia 
and lymphoma. 
TEL fusion protein partners (PDGFbetaR, TRK.c, 
ABL, and JAK2) in leukemia and fibrosarcoma 
Promyelocytic leukemia, acute myelocytic leukemia 
Burkitt lymphoma, B-celllymphoma, multiple 
myeloma, medulloblastoma, neuroblastoma, 
colorectal, ovarian and intestinal cancer 
The target ETS transcription factor specifically modulated 
may be FLil transcription factor or ERG transcription 
factor. In an embodiment of this aspect, a therapeutically 
effective amount of MTM SA-Trp or MTM SA-Phe or a 
derivative or salt thereof is administered to a Ewing sarcoma 
patient. In other embodiments, a therapeutically effective 
amount ofMTM SA-Trp or MTM SA-Phe or a derivative or 
salt thereof is administered to a patient with any of the 
diseases listed in Table 1. 
In general, the MTM SA derivatives of the present dis-
closure can be used for the treatment of a target ETS 
transcription factor-mediated disease including Ewing sar-
coma, clear-cell sarcoma, myxoid liposarcoma, desmoplas-
tic small round cell tumor, myxoid chondrosarcoma, acute 
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myeloid leukemia, congenital fibrosarcoma, prostate cancer, 
pancreatic cancer, acute myeloid leukemia (AML), acute 
lymphoblatic leukemia (ALL), Alzheimer's disease (AD), or 
Down syndrome (DS) or other hyperproliferative disease in 
which an aberrant activity of a target ETS transcription 
factor is implicated. A "hyperproliferative disease" includes 
diseases and conditions that are associated with any sort of 
abnormal cell growth or abnormal growth regulation, spe-
cifically a cancer. 
In certain embodiments, the present disclosure provides a 10 
method of treating a hyperproliferative disease mediated by 
an aberrant activity of a target ETS transcription factor 
comprising administering to a subject in need thereof a 
therapeutically effective amount of a composition compris-
ing an MTM SA derivative such that the activity of the target 15 
transcription factor is reduced or inhibited; wherein the 
MTM SA derivative is MTM SA-Phe, MTM SA-Trp, MTM 
SA-Ala, MTM SA-Tyr or MTM SA-Phe-Allylox and 
wherein the target ETS-mediated disease is Ewing sarcoma, 
clear-cell sarcoma, myxoid liposarcoma, desmoplastic small 20 
round cell tumor, myxoid chondrosarcoma, acute myeloid 
leukemia, congenital fibrosarcoma, prostate cancer or pan-
creatic cancer. In certain other embodiments, the present 
disclosure provides a method of treating Ewing sarcoma 
comprising administering to a subject in need thereof a 25 
therapeutically effective amount of a composition compris-
ing an MTM SA derivative selected from the group con-
sisting of MTM SA-Phe, MTM SA-Trp, MTM SA-Ala, 
MTM SA-Tyr, MTM SA-Phe-Allylox or a derivative 
thereof, wherein the derivative comprises one or more sugar 30 
groups comprising digitoxos or other derivative described 
herein. In an embodiment of this aspect, the target ETS 
transcription factor specifically modulated is Friend leuke-
mia integration 1 transcription factor (FLil) or v-ets avian 
erythroblastosis virus E26 oncogene-like transcription factor 35 
(ERG). In an embodiment, the present disclosure provides a 
method of treating a hyperproliferative disease mediated by 
an aberrant activity of a target ETS transcription factor 
comprising administering to a subject in need thereof a 
therapeutically effective amount of a composition compris- 40 
ing MTM SA-Phe and/or MTM SA-Phe allylox or compris-
ing MTM SA-Trp such that the activity of the target tran-
scription factor is reduced or inhibited; wherein the ETS 
target transcription factor is FLil or ERG. 
As described above, the screening method of the subject 45 
technology identifies MTM SA derivatives that are more 
specific than MTM for complexing with a target EST 
transcription factor and, therefore, inhibiting its activity. The 
specific or selective MTM SA derivatives of the subject 
technology are useful for treating diseases that are mediated 50 
by, for example, FLil or ERG, such as Ewing sarcoma, 
clear-cell sarcoma, myxoid liposarcoma, desmoplastic small 
round cell tumor, myxoid chondrosarcoma, acute myeloid 
leukemia, congenital fibrosarcoma, prostate cancer, pancre-
atic cancer, acute myeloid leukemia (AML), acute lympho- 55 
blatic leukemia (ALL), Alzheimer's disease (AD), or Down 
syndrome (DS) or other hyperproliferative disease in which 
an aberrant activity of a target ETS transcription factor is 
implicated. 
Other hyperproliferative diseases which may be benefited 60 
by the methods and compounds of the subject technology 
include, though it is not limited to, neoplasm, malignant; 
carcinoma; carcinoma, undifferentiated; giant and spindle 
cell carcinoma; small cell carcinoma; papillary carcinoma; 
squamous cell carcinoma; lymphoepithelial carcinoma; 65 
basal cell carcinoma; pilomatrix carcinoma; transitional cell 
carcinoma; papillary transitional cell carcinoma; adenocar-
20 
cinoma; gastrinoma, malignant; cholangiocarcinoma; 
hepatocellular carcinoma; combined hepatocellular carci-
noma and cholangiocarcinoma; trabecular adenocarcinoma; 
adenoid cystic carcinoma; adenocarcinoma in adenomatous 
polyp; adenocarcinoma, familial polyposis coli; solid carci-
noma; carcinoid tumor, malignant; branchiolo-alveolar 
adenocarcinoma; papillary adenocarcinoma; chromophobe 
carcinoma; acidophil carcinoma; oxyphilic adenocarci-
noma; basophil carcinoma; clear cell adenocarcinoma; 
granular cell carcinoma; follicular adenocarcinoma; papil-
lary and follicular adenocarcinoma; nonencapsulating scle-
rosing carcinoma; adrenal cortical carcinoma; endometroid 
carcinoma; skin appendage carcinoma; apocrine adenocar-
cinoma; sebaceous adenocarcinoma; ceruminous adenocar-
cinoma; mucoepidermoid carcinoma; cystadenocarcinoma; 
papillary cystadenocarcinoma; papillary serous cystadeno-
carcinoma; mucinous cystadenocarcinoma; mucinous 
adenocarcinoma; signet ring cell carcinoma; infiltrating duct 
carcinoma; medullary carcinoma; lobular carcinoma; 
inflammatory carcinoma; paget's disease, mmary; acinar 
cell carcinoma; adenosquamous carcinoma; adenocarci-
noma w/squamous metaplasia; thymoma, malignant; ovar-
ian stromal tumor, malignant; thecoma, malignant; granu-
losa cell tumor, malignant; androblastoma, malignant; 
Sertoli cell carcinoma; Ieydig cell tumor, malignant; lipid 
cell tumor, malignant; paraganglioma, malignant; extra-
mammary paraganglioma, malignant; pheochromocytoma; 
glomangiosarcoma; malignant melanoma; amelanotic mela-
noma; superficial spreading melanoma; malignant mela-
noma in giant pigmented nevus; epithelioid cell melanoma; 
blue nevus, malignant; sarcoma; fibrosarcoma; fibrous his-
tiocytoma, malignant; myxosarcoma; liposarcoma; leiomyo-
sarcoma; rhabdomyosarcoma; embryonal rhabdomyosar-
coma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed 
tumor, malignant; mullerian mixed tumor; nephroblastoma; 
hepatoblastoma; carcinosarcoma; mesenchymoma, malig-
nant; breunertumor, malignant; phyllodes tumor, malignant; 
synovial sarcoma; mesothelioma, malignant; dysgermi-
noma; embryonal carcinoma; teratoma, malignant; struma 
ovarii, malignant; choriocarcinoma; mesonephroma, malig-
nant; hemangiosarcoma; hemangioendothelioma, malig-
nant; kaposi's sarcoma; hemangiopericytoma, malignant; 
lymphangiosarcoma; osteosarcoma; juxtacortical osteosar-
coma; chondrosarcoma; chondroblastoma, malignant; mes-
enchymal chondrosarcoma; giant cell tumor of bone; 
ewing's sarcoma; odontogenic tumor, malignant; ameloblas-
tic odontosarcoma; ameloblastoma, malignant; ameloblastic 
fibrosarcoma; pinealoma, malignant; chordoma; glioma, 
malignant; ependymoma; astrocytoma; protoplasmic astro-
cytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; 
oligodendroglioma; oligodendroblastoma; primitive neu-
roectodermal; cerebellar sarcoma; ganglioneuroblastoma; 
neuroblastoma; retinoblastoma; olfactory neurogenic tumor; 
meningioma, malignant; neurofibrosarcoma; neurilem-
moma, malignant; granular cell tumor, malignant; malignant 
lymphoma; hodgkin's disease; hodgkin's; paragranuloma; 
malignant lymphoma, small lymphocytic; malignant lym-
phoma, large cell, diffuse; malignant lymphoma, follicular; 
mycosis fungoides; other specified non-hodgkin's lympho-
mas; malignant histiocytosis; multiple myeloma; mast cell 
sarcoma; immunoproliferative small intestinal disease; leu-
kemia; lymphoid leukemia; plasma cell leukemia; erythro-
leukemia; lymphosarcoma cell leukemia; myeloid leukemia; 
basophilic leukemia; eosinophilic leukemia; monocytic leu-
kemia; mast cell leukemia; megakaryoblastic leukemia; 
myeloid sarcoma; and hairy cell leukemia. 
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pharmaceutically acceptable salt thereof. In other embodi-
ments, the active compound may comprise between about 
1% to about 75% of the weight of the unit dosage, or 
between about 5% to about 50% by weight of the unit 
dosage, for example, and any specific percentage in between 
these ranges. In other non-limiting examples, a dose may 
also comprise from about 0.01 microgram/kg/body weight, 
about 50 microgram/kg/body weight, about 100 microgram/ 
kg/body weight, about 500 microgram/kg/body weight, 
In another aspect of the present disclosure, an effective 
amount of the MTM SA derivative or a pharmaceutically 
acceptable salt thereof is administered to a patient in need of 
cancer treatment or a neuro-disease, such as Huntington'd 
disease. The MTM SA derivatives or pharmaceutically 
acceptable salts thereof of the present disclosure can be 
administered to a patient, e.g., a human patient, in need of 
such treatment by any route. The MTM SA derivatives or 
pharmaceutically acceptable salts thereof of the present 
disclosure can be administered alone or with a pharmaceu-
tically acceptable carrier or excipient. 
Dosage Form and Formulation of MTM SA 
An MTM SA derivative of the subject technology such as 
MTM SA-Phe, MTM SA-Trp or a derivative thereof can be 
administered to a patient in need thereof in any possible 
dosage form including, but not limited to ingestible tablets, 
buccal tablets, troches, capsules, elixirs, suspensions, syr-
ups, wafers, infusion, aqueous liquid and the like. Solutions 
10 about 1 milligram/kg/body weight, about 5 milligram/kg/ 
body weight, about 10 milligram/kg/body weight, about 30 
milligram/kg/body weight, about 40 milligram/kg/body 
weight, about 50 milligram/kg/body weight, about 100 mil-
ligram/kg/body weight, or more per administration, and any 
of an MTM SA such as MTM SA-Phe or MTM SA-Trp can 
15 range or specific amount derivable therein. In non-limiting 
examples of a derivable range from the numbers listed 
herein, a range of about 5 microgram/kg/body weight to 
about 5 milligram/kg/body weight, about 50 microgram/kg/ 
body weight to about 50 milligram/kg/body weight, etc., can 
20 be administered. be prepared in water and mixed with suitable excipients. 
Under ordinary conditions of storage and use, these prepa-
rations can contain a preservative to prevent the growth of 
microorganisms or retain stabilization of the MTM SA 
derivative. The pharmaceutical forms suitable for injection 
include sterile aqueous solutions or dispersions and sterile 25 
powders for the extemporaneous preparation of sterile 
injectable solutions or dispersions. The form should be 
sterile and should be fluid to the extent it makes injection 
possible. 
A composition containing an MTM SA derivative of the 30 
disclosure such as MTM SA-Phe, MTM SA-Trp or a phar-
maceutically acceptable salt thereof can be prepared by 
known methods, such that an effective quantity of the 
therapeutic agent is delivered to a subject. Suitable vehicles 
for such a composition are described, for example, in 35 
Remington's Pharmaceutical Sciences (2003) and in the 
Handbook of Pharmaceutical Additives (compiled by 
Michael and Irene Ash, Gower Publishing Limited, Alder-
shot, England (1995)). 
In some embodiments, the composition of this disclosure 40 
enables sustained, continuous delivery of an MTM SA 
derivative such as MTM SA-Phe, MTM SA-Trp or a phar-
maceutically acceptable salt thereof to tissues adjacent to or 
distant from an administration site. The biologically-active 
agent is capable of providing a local or systemic biological, 45 
physiological or therapeutic effect. For example, MTM 
SA-Phe or MTM SA-Trp may act to kill cancer cells or 
cancer stem cells or to control or suppress tumor growth or 
metastasis, among other functions. 
In some embodiments, the formulations of the present 50 
disclosure are administered in an amount effective to pro-
vide the desired level of biological, physiological, pharma-
cological and/or therapeutic effect such as inhibition of a 
target ETS transcription factor. 
The actual dosage amount of a composition of the present 55 
disclosure administered to a patient or subject can be deter-
mined by physical and physiological factors such as body 
weight, severity of condition, the type of disease being 
treated, previous or concurrent therapeutic interventions, 
idiopathy of the patient and on the route of administration. 60 
The practitioner responsible for administration will, in any 
event, determine the concentration of active ingredient( s) in 
a composition and appropriate dose(s) for the individual 
subject. 
In certain embodiments, pharmaceutical formulations 65 
include, for example, at least about 0.1% of an active 
compound, such as MTM SA or derivatives thereof or 
For a safe and effective dosage, the formulations can be 
administered at an MTM SA derivative dose of about 0.01 
to about 500 mg/m2 (body surface)/day, about 0.01 to about 
300 mg/m2/day, 0.01 to about 200 mg/m2/day, about 1 to 
about 200 mg/m2/day about 10 to about 100 mg/m2/day, 
about 25 to about 100 mg/m2/day or any range derivable 
therein to a subject such as a human. In certain aspects, the 
composition may be administered at a dose of about 0.01 to 
about 200 mg/kg body weight, about 0.01 to about 100 
mg/kg body weight, 1 to about 50 mg/kg body weight, about 
1 to about 20 mg/kg body weight, about 3 to about 10 mg/kg 
body weight, about 3 to about 6 mg/kg body weight or any 
range derivable therein to a subject such as a human. In some 
embodiments, a formulation of the subject technology may 
be administered in a dose of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 
20, 25, 30, 40, 50, 60, 70, 80, 90, 100 mg or more per day. 
Each liquid dose may be in a volume of 1, 10, 50, 100, 200, 
500, 1000 or more fll or mi. 
In some embodiments, the pharmaceutical formulation of 
the subject technology includes an MTM SA derivative such 
as MTM SA-Phe or MTM SA-Trp in an amount effective to 
result in a serum concentration of the MTM SA in the 
mammal in a range of from 1 nM to 1 mM, particularly 1 nM 
to 2 f.LM. 
Serum and systemic circulation concentrations of MTM 
SA derivatives effective to result in the treatment of a target 
ETS transcription factor-mediated disease may vary depend-
ing on a number of factors. Influential variables can include, 
for example, pKa, solubility or molecular weight of the 
MTM SA derivative. These properties of a particular MTM 
SA derivative such as MTM SA-Phe or MTM SA-Trp may 
affect how a patient metabolizes the compound, how much 
of the compound enters and remains in the systemic circu-
lation of the patient, and how effectively the compound 
treats, prevents or causes regression of the disease, e.g., 
Ewing sarcoma, tumor or cancer. 
Precise amounts of the therapeutic composition also 
depend on the judgment of the practitioner and are peculiar 
to each individual. Factors affecting the dose include the 
physical and clinical state of the patient, the route of 
administration, the intended goal of treatment (e.g. allevia-
tion of symptoms versus cure) and the potency, stability and 
toxicity of the particular therapeutic substance. 
Route of Administration 
In accordance with the methods of the disclosure, the 
described composition or formulation of the subject tech-
nology may be administered to a subject in a variety of 
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forms depending on the selected route of administration, as 
will be understood by those skilled in the art. It may be 
administered, for example, by oral, parenteral, buccal, sub-
lingual, nasal, rectal, patch, pump, or transdermal adminis-
tration and the pharmaceutical compositions formulated 
accordingly. Parenteral administration includes intravenous, 
intraperitoneal, subcutaneous, intramuscular, intratumoral, 
transepithelial, nasal, intrapulmonary, intrathecal, rectal and 
topical modes of administration. Parenteral administration 
may be by continuous infusion over a selected period of 
time. 
Combination Therapies 
In certain embodiments, the compounds, compositions or 
formulations of the subject technology are administered with 
a second or additional active agent(s) such as with one or 
more different MTM SA derivatives or another anticancer 
agent. Such therapy can be applied in the treatment of any 
disease for which treatment with an MTM SA derivative 
such as MTM SA-Phe or MTM SA-Trp is contemplated. For 
example, the disease may be a hyperproliferative disease, 
such as Ewing sarcoma or prostate cancer. 
In certain embodiments, the additional active agent may 
be a chemotherapeutic agent or a radiation therapy. 
Examples of chemotherapeutic agents include, but are not 
limited to, cetuximab ( erbitux), herceptin (trastuzumab ), 
fludarabine, cyclophosphamide, rituximab, imatinib, Dasa-
tinib (BMS0354825), cisplatin (CDDP), carboplatin, pro-
carbazine, mechlorethamine, camptothecin, ifosfamide, 
melphalan, chlorambucil, busulfan, nitrosurea, dactinomy-
cin, daunorubicin, doxorubicin, bleomycin, plicomycin, 
mitomycin, etoposide (VP 16), tamoxifen, raloxifene, estro-
gen receptor binding agents, taxol, gemcitabien, navelbine, 
farnesyl-protein tansferase inhibitors, transplatinum, 5-fluo-
rouracil, vincristin, vinblastin, methotrexate, an analogue or 
derivative thereof. In certain embodiments, the active or 
anticancer agent(s) that may be used in combination with an 
MTM SA derivative may be fludarabine, cyclophosphamide, 
rituximab, imatinib or Dasatinib. In a certain aspect, the 
cancer may be resistant to a particular chemotherapeutic 
agent, such as fludarabine, cyclophosphamide, rituximab, 
imatinib or Dasatinib. 
Polypeptides 
24 
wild-type or mutant polypeptide on a growth medium 
depleted of one or more natural amino acids but enriched in 
one or more corresponding unnaturally occurring amino 
acids. The expression or the activity (e.g., DNA binding) of 
the engineered polypeptide may be determined using the 
methods described in the Examples. 
For increased stability and half-life, the engineered poly-
peptides of the subject technology may be modified by 
chemical moieties and/or functional groups such as an 
10 amine, carboxyl, thiol or hydroxyl group. See, e.g., Kochen-
doerfer eta!., Science, 299: 884-887 (2003) which is incor-
porated herein by reference in its entirety. Chemicals useful 
in making such modifications include, but are not limited to, 
polymers like polyethylene glycol (PEG), polypeptides such 
15 as the Fe portion of an antibody or chemical groups. These 
modifications will increase the stability and half-life of the 
polypeptides of the subject technology. 
Polynucleotides 
Another aspect of the subject technology provides poly-
20 nucleotide sequences encoding the engineered ETS tran-
scription factors of the subject technology. Further included 
in the subject technology are polynucleotides encoding the 
engineered ETS transcription factors of the present disclo-
sure that are fused in frame to the coding sequences for 
25 additional heterologous amino acid sequences. Also 
included are nucleic acids encoding the engineered ETS 
transcription factors of the present disclosure together with 
additional, non-coding sequences, including, but not limited 
to, non-coding 5' and 3' sequences, vector sequence, 
30 sequences used for purification, probing, or priming. For 
example, heterologous sequences include transcribed, 
untranslated sequences that may play a role in transcription 
and mRNA processing, such as ribosome binding and sta-
bility of mRNA. The heterologous sequences may alterna-
35 tively comprise additional coding sequences that provide 
additional functionalities. Thus, a nucleotide sequence 
encoding a polypeptide may be fused to a tag sequence, such 
as a sequence encoding a peptide that facilitates purification 
or detection of the fused polypeptide. In certain embodi-
40 ments of this aspect of the subject technology, the tag amino 
acid sequence is a hexa-histidine peptide (SEQ ID NO: 10), 
such as the tag provided in a pQE vector (QIAGEN), or in 
any of a number of additional, commercially available 
vectors. 
In some embodiments, the subject technology provides an 
engineered ETS transcription factor comprising a DNA 
binding domain of SEQ ID N0:01 or SEQ ID N0:02, 45 
wherein the ETS transcription factor includes at least one 
amino acid substitution at any of amino acid residues 
corresponding to residues Tyr68, Lys75, His77, Gly78, 
Lys79, Arg80, Tyr81, Ala82 of its DNA binding domain. In 
some other embodiments, the subject technology provides 50 
an engineered ETS transcription factor comprising a DNA 
binding domain with an amino acid sequence that is at least 
85% identical to SEQ ID NO:Ol or SEQ ID N0:02 over the 
entire length of either of these sequences, and has at least 
one amino acid substitution at any of the amino acid residues 55 
of its DNA binding domain that correspond to residues 
Tyr68, Lys75, His77, Gly78, Lys79, Arg80, Tyr81, Ala82 of 
SEQ ID NO:Ol or SEQ ID N0:02. 
Polynucleotides of the subject technology will be gener-
ally at least 60% or 70%, preferably at least 80 or 90% and 
more preferably at least 95% or 98% homologous to the 
nucleotide sequences encoding an engineered ETS tran-
scription factor described above, over a region of at least 20, 
preferably at least 25 or 30, for instance at least 40, 60 or 100 
or more contiguous nucleotides. Polynucleotides of the 
subject technology will be capable of encoding an engi-
neered ETS transcription factor with a DNA binding domain 
comprising a DNA binding domain with an amino acid 
sequence that is at least 85% identical to SEQ ID N0:01 or 
SEQ ID N0:02 over the entire length of either of these 
sequences and has at least one amino acid substitution at any 
of amino acid residues corresponding to residues Tyr68, 
Lys75, His77, Gly78, Lys79, Arg80, Tyr81, Ala82 of SEQ 
ID N0:01 or SEQ ID N0:02. 
The engineered ETS transcription factors of the subject 
technology may be prepared in a number of ways that are 60 
known by a person skilled in the art. For example, mutations 
may be introduced by means of oligonucleotide-directed 
mutagenesis or other conventional methods. Alternatively, 
engineered ETS transcription factors may be generated by 
site specific replacement of a particular amino acid with an 65 
unnaturally occurring amino acid. This may be achieved by 
growing a host organism capable of expressing either the 
Constructs 
In another aspect of the subject technology, the coding 
polynucleotide sequences encoding the engineered ETS 
transcription factors of the subject technology may be oper-
ably linked to a promoter in a DNA construct using con-
ventional cloning technology. The promoter may be a 
homologous or a heterologous promoter, i.e., a promoter not 
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natively associated with the coding sequence. The promoter 
may be constitutive or inducible. Suitably, the promoter 
includes an expression control sequence near the start site of 
transcription. A promoter may include enhancer or repressor 
elements that may be non-contiguous with the start site of 5 
transcription. The polynucleotide may be provided within a 
vector, for example, a plasmid, cosmid, or virus. 
tryptic soy broth (TSB) and grown for 24 hr in an orbital 
shaker at 2S° C., 250 rpm. After 24 hrs 4 mL of the TSB 
culture was used to start a culture in R5A media in 40, 100 
mL flasks. The cultures in R5Amedia were grown for 3 days 
at 2S° C., 250 rpm while the production of SA was moni-
tored by HPLC. After 3 days the cells were collected with 50 
g/L of celite and removed by filtration. The cell pellet was 
then re-dissolved in MeOH and sonicated for 1 hr to lyse the 
cells. Following the cell lysis the cellular debris was filtered 
Kits 
The subject technology also encompasses kits for assess-
ing the effect of a test agent, i.e., an MTM SA derivative or 
a pharmaceutically accepted salt thereof, on the activity of 
target ETS transcription factor or its complex formation with 
a DNA substrate and the test agent. In some embodiments, 
the kit comprises a detectably labeled or unlabeled test agent 
and/or a detectably labeled or unlabeled DNA substrate 
and/or a detectably labeled target ETS transcription factor 
such as FLil or ERG. The kit can further comprise instruc-
tions for using the kit to detect target protein or nucleic acid. 
In particular, the kit comprises an engineered ETS transcrip-
tion factor comprising a DNA binding domain of SEQ ID 
NO:Ol or SEQ ID N0:02, wherein the transcription factor 
includes at least one amino acid substitution at any of amino 
acid residues corresponding to residues Tyr6S, Lys75, 
His77, Gly7S, Lys79, ArgSO, TyrSl, AlaS2 of SEQ ID 
NO:Ol or SEQ ID N0:02. 
EXAMPLES 
The following examples are intended to further illustrate 
certain preferred embodiments of the invention and are not 
limiting in nature. Those skilled in the art will recognize, or 
be able to ascertain, using no more than routine experimen-
tation, numerous equivalents to the specific substances and 
procedures described herein. 
Example 1 
Biosynthesis of MTM SA Derivatives 
Materials and Methods 
N,N'-diisopropylcarbodiimide (DIC), N-hydroxysuccin-
imide (NHS), dimethylformamide (DMF), dichloromethane 
(DCM), 0-(Benzotriazol-1-yl)-N,N,N' ,N"-tetramethyluro-
nium tetrafluoroborate (TBTU), COMU, diphenyl phospho-
10 off and the MeOH was evaporated from the filtrate. The 
dried cellular extract was then reconstituted in water and 
loaded onto a 5x12 em CIS RP column equilibrated with 10 
column volumes of water. The column was washed with 
10% ACN in water, followed by a fractionation of ACN in 
15 water from 20-50%, followed by 100% ACN. The filtrate 
removed from the cells in step one was added to the CIS 
column and eluted by the same fractionation procedure. The 
samples were dried and re-constituted in SO% MeOH and 
water. SA was then completely isolated from the mixture of 
20 a few compounds by semi-preparative HPLC. 
Synthetic Modification of MTM SA 3 Side Chain 
MTM SA was modified by converting the terminal car-
boxylic acid group with a primary amine through a coupling 
reaction. Several different protocols were investigated to 
25 discover the optimal reaction conditions. For all of the 
exploratory reactions 2 mg ofMTM SA was used. The initial 
reaction was completed by reacting MTM SA with the 
desired side chain modifying molecule in a 3x molar ratio, 
3xDIPEA and lxTBTU in 500 DCM starting at 4o C. The 
30 reaction was monitored at 2 h by HPLC-MS and allowed to 
proceed a total 24 h with the products analyzed by HPLC-
MS. For HPLC-MS analysis a small aliquot was removed 
from the reaction mixture, the solvent dried off, and then 
reconstituted in methanol for analysis. For the initial reac-
35 tion an extract on with ethyl acetate and the separation of the 
aqueous and organic phase was attempted, however this was 
not repeated with the subsequent reactions. The reaction was 
then repeated with 3xDIPEA, lOx of the side chain modi-
fication molecule, and 2x of the coupling agent DPPA in 
40 DMF, starting at 4° C. and monitored at 24 and 36 h. The 
protocol was modified and optimized by returning to 3x of 
the desired side chain modification molecule and while 
substituting the coupling agents COMU or PyBOP and the 
solvent DCM or DMF in different combinations. The reac-
45 tions were checked at 24 and 4S h. After the reactions were ryl azide (DPPA), N,N-diisopropylethylamine (DIPEA), 
methyl hydrazine, benzotriazol-1-yl-oxytripyrrolidinophos-
phonium hexafluorophosphate (PyBOP), L-cysteine methyl 
ester hydrochloride, L-glycine methyl ester hydrochloride, 
L-alanine methyl ester hydrochloride, L-valine methyl ester 
hydrochloride, cystamine, DMSO (molecular biology grade, 50 
99.9%), dimethylsulfoxide-d6 (DMSO-d6 ), resazurin 
sodium salt, were purchased from Sigma-Aldrich (USA). 
N,N-dimethylethylenediamine was purchased from TCI 
America (USA). 1-amino-2-propanone was purchased from 
Waterstone Tech (USA). Methanol (MeOH), acetonitrile 55 
(ACN), celite, CIS RP silica gel, tryptic soy broth (TSB), 
LB broth, Difco agar, sucrose, potassium sulfate, magne-
sium chloride, glucose, casamino acids, yeast extract, 
MOPS, and trace elements were purchased from Fisher 
Scientific (USA). Streptomyces argillaceus ATCC 12956, 60 
A549 tissue culture cells, F-12K media, fetal bovine serum 
(FBS) were purchased from ATCC (USA). 
completed the solvent was removed and the product mixture 
was reconstituted in methanol. The mixture was analyzed by 
HPLC-MS using a combination of the mass and UV absor-
bance to identifY the elution peaks corresponding to the 
expected products. HPLC was then used to isolate the 
individual compounds. The organic solvents were removed 
from the samples followed by the freeze drying of the 
compounds. To scale up the production of the compounds 10 
mg of SA was reacted with 3x of the side chain molecule, 
3xDIPEA, 2x PyBOP in DCM, starting at 4o C., for 24 h. 
The solvent was removed and the products were reconsti-
tuted in methanol and isolated by HPLC. The side chain 
modification molecules included methyl hydrazine, L-cys-
teine methyl ester, L-glycine methyl ester, L-alanine methyl 
ester, L-valine methyl ester, cystamine, N,N-dimethylethyl-
enediamine, and 1-amino-2-propanone (FIG. 2). 
Structure Confirmation 
Biosynthesis of MTM SA 
MTM SA was produced by an adapted procedure reported 
previously. S. argillaceus M7Wl was plated on R5A agar 65 
and allowed to grow for four days or until spores formed. 
The spores were then used to seed a culture in 100 mL of 
The structures of the most active derivatives from the 
reactions with MTM SA and L-glycine methyl ester, L-ala-
nine methyl ester, and L-valine methyl ester were confirmed 
through H1 and C13 NMR along with MALDI-TOF mass 
spectrometry performed by the University of Kentucky 
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Mass Spectrometry Facility. The NMR measurements were 
taken on a 500 MHz NMR in methanol-d4 
In Vitro Cytotoxicity Assays 
The cytotoxic effects of the side chain modifications of 
SA were investigated in order to determine whether the 5 
modification were beneficial to the drug structure. All cyto-
toxicity assays were performed with A549, human non-
small cell lung cancer cells. A549 cells were cultured as 
specified from ATCC at 37° C., 5% C02 . The cells were 
added to a 96 well plate (5,000 cells/well) and permitted to 10 
attach for 24 h. After 24 h culture media were replaced with 
the side chain modified MTM SA derivative containing 
media at differing concentrations. The cells were incubated 
with the drug containing media for 72 hrs total (n=S). Cell 
viability was determined using a resazurin assay that signi- 15 
fies mitochondrial metabolic activity in living cells. I 0 pL of 
28 
formed by using semi-preparative HPLC. The individual 
peak corresponding to MTM SA was collected and analyzed 
for purity using HPLC-MS. MTM SA was able to be 
collected at >95% purity and was stored at 20° C. until 
further use. 
Synthetic Modification of MTM SA 3 Side Chain (I) 
Once produced, MTM SA was modified chemically by 
taking advantage of the terminal carboxylic acid on the 
3-side chain of the molecule. Several different protocols 
were attempted in order to discern the most favorable 
reaction conditions. The reactions were monitored by HPLC 
and the ratio of the signal corresponding to MTM SA was 
compared to the appearance of any new peaks following the 
reaction. MTM SA eluted with a retention time of 16.5 min, 
showing absorption of 410 nm and a mass to charge ratio of 
m/z 1026. The initial reaction with methyl hydrazine and 
TBTU as a coupling agent in DCM only displayed SA as the 
major component of the mixture after 2 h with only very 
minor other peaks appearing. After 24 h the MTM SA peak 
was gone with several broad peaks with shorter retention 
times appeared. The initial attempt to separate the products 
by ethyl acetate extraction did not result in favorable results 
and thus was not repeated. The reaction was then repeated 
a I mM resazurin solution in PBS was added to the control 
and analogue-treated cells at the end of the treatment period. 
Cell viability was determined three hours later by reading 
the fluorescence at 560 nm (Ex)/590 nm (Em). The fluores- 20 
cence signals were quantified using a Spectramax M5 plate 
reader (Molecular Devices) equipped with a SoftMaxPro 
software. Cytotoxicity was determined by calculating the 
half maximal inhibitory concentration (IC50) of each 
sample. 25 with methyl hydrazide with the DPPA coupling agent in 
DMF. The reaction was also performed with 1-amino-2-
propanone under the same conditions. After 24 h a new peak 
at 14.0 min appeared equal in intensity to that of the MTM 
Biotechnological Production of MTM SA 
MTM SA was successfully produced by the S. argillaceus 
M7WI and isolated through an adapted procedure devel-
oped previously. Spores of S. argillaceus were formed by 
plating the cells of the M7WI mutant strain on R5A agar and 30 
allowing them to grow until spores were formed. Colonies 
of the S. argillaceus cells began to appear after incubation 
for two days and after three days spores were observed. The 
cells were allowed to incubate for one more day to allow the 
majority of the cells to exist as spores and then added to TSB 35 
media. Once transferred to the TSB the cells grew quickly 
and after 24 h the TSB culture was used to inoculate multiple 
flasks of R5A media to produce SA. The pH of the R5A 
media was adjusted to pH 6.S5. HPLC was used to monitor 
the culture for the production of SA. After 72 h the culture 40 
production was primarily composed of the end products 
including MTM SK and MTM SDK in addition to MTM 
SA, and the culture was terminated. A large portion of the 
MTM SA production is excreted into the culture media so 
once the culture process was stopped the media and the cells 45 
were separated. Celite cell binding resin was used to bind the 
cells and allow the culture to more easily be separated 
through filtration. CIS RP silica gel was able to successfully 
collect MTM SA from the complex culture mixture. Other 
compounds were also collected by the column so initial 50 
washes of I 0% and 20% ACN were used to remove many of 
the byproducts from the sample. Further fractionation of the 
culture on the CIS RP column in addition to the loading and 
subsequent fractionation on a new, smaller CIS RP column 
SA peak. The expected product had a m/z of 1054.4, the 
same as the 14.0 min peak of 1054.4. The absorption of the 
peak was shifted however to 440 nm. The reaction with the 
1-amino-2-propanone did not produce a new peak even after 
36 hrs. The reaction was then repeated using the coupling 
agent COMU in DMF with the side chains L-glycine methyl 
ester hydrochloride and N,N-dimethylethylenediamine. For 
the reaction with N,N-dimethylethylenediamine a new prod-
uct appeared with a retention time of 11.25 min, a UV-Vis 
absorption of 410 nm and a m/z matching that of the 
expected product of 1096.6 (1096.5 expected). For the 
reaction with L-glycine methyl ester hydrochloride three 
new products were formed with retention times of 14.4, 
15.6, and 17.0 min. The UV-Vis absorption for the peaks 
were 455 nm, 455 nm, and 410 nm with 1097.3, 116S.4, and 
1097.3 m/z, respectively. The calculated m/z for the correct 
product of the reaction with L-glycine methyl ester hydro-
chloride is 1097.4 m/z. There was still also a small peak 
corresponding to MTM SA. The reaction of MTM SA with 
cystamine was performed in DMF with COMU and resulted 
in the formation of a new peak at 9.0 min with absorption of 
455 nm and m/z 1160.6. The theoretical m/z of the expected 
product was IOS5.S but if a disulfide bond were to form 
between an attached side chain molecule and a free side 
chain molecule the expected m/z would be 1160.4 m/z. The 
reaction solvent was then switched to DCM and L-alanine 
did not aid in the isolation of MTM SA from the other MTM 55 methyl ester hydrochloride was used as the side chain 
analogues so all compounds were eluted to together with 
I 00% ACN to minimize dilution. There was also still some 
MTM SA contained inside the cells removed in the initial 
filtration step so the cells were lysed by sonication in 
methanol to release the intracellular content including all the 60 
MTM SA. Filtration removed the cellular debris, followed 
by the removal of the methanol. The same procedure as with 
the culture media then resulted in a relatively simple mixture 
of MTM SA along with the other MTM analogues and a few 
other impurities. Since the fractionation of the sample on the 65 
CIS RP silica gel did not completely isolate MTM SA from 
the other analogues the final purification steps were per-
modification molecule. This reaction resulted in the forma-
tion of one new peak with a retention time of IS min at 
roughly equal intensity to that of the MTM SA peak and a 
UV-Vis of 410 nm and a m/z of 1111.3. The calculated m/z 
of the expected molecule was 1111.4. The same conditions 
were used with L-valine methyl ester hydrochloride as well 
which resulted in a new molecule with a retention time of 
20.6 min, a UV-Vis absorption of 410 nm and a m/z of 
113 9. 5. The peak was the major product compared to the SA 
peak. The calculated m/z of the expected product was 
1139.5. The reactions with L-glycine methyl ester hydro-
chloride and N,N-dimethylethylenediamine were then 
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repeated with DCM as the solvent and PyBOP as the 
coupling agent. These reactions resulted in the formation of 
one new product with a retention time of 11.0 min for the 
N,N-dimethylethylenediamine reaction and 17.0 min for the 
L-glycine methyl ester hydrochloride reaction. Both prod-
ucts at a UV-Vis absorption of 410 nm and the m/z of the 
expected products identified previously. The individual 
peaks were collected from HPLC, the ACN removed, and 
freeze dried for use with the in vitro cytotoxicity assays. 
30 
side chain modified molecules including MTM SA-Ala, 
-Ser, -Cys, -His, -Trp, -Tyr, -Phe, -PheGly, -Phe-Allylox are 
shown in FIG. 2. 
Structure Confirmation by NMR 
The structures ofMTM SA-L-glycine methyl ester hydro-
chloride, MTM SA-L-alanine methyl ester hydrochloride, 
and MTM SA-L-valine methyl ester hydrochloride were 
confirmed by H1 and C13 NMR. The mass of the derivatives 
was also confirmed by mass spectrometry. For MTM SA-L-
glycine methyl ester hydrochloride the expected mass+Na 
was 1120.45 and the observed mass was 1120.45, for MTM 
SA-L-alanine methyl ester hydrochloride the expected prod-
uct had a calculated mass+Na of 1134.47 and the observed 
mass was 1134.47, and for MTM SA-L-valine methyl ester 
15 hydrochloride 1162.50 and observed mass was also 1162.50. 
Exemplary routes for synthesizing MTM SA and its use 10 
for 3-side chain derivatization are depicted in FIG. 2. 
Briefly, the mtm W deletion mutant of Streptomyces argil-
laceus M7W1 will be used, which produces -50% MTM SA 
along with each 25% of MTMs SK and SDK. The unique 
carboxyl moiety ofMTM SA allows a simple derivation into 
amides or esters. Initially short amide side chains will be 
generated using PyBop (benzotriazol-1-yl-oxytri -pyrroli-
dina-phosphonium hexafluoro-phosphate) or similar selec-
tive coupling reagents. The approach allows introducing 20 
N-atoms and other hydrogen bond donor and/or acceptor 
atoms into the side chain, thereby modifying its protein-
binding properties. As an alternative to isolating MTM SA 
from the M7W1 mutant, the inventors also designed an 
enzymatic strategy using the premithramycin B (5) produc- 25 
ing mtmOIV deletion mutantS. argillaceus M704 (produc-
tion -100 mg/L 5). FIG. 2 shows some examples of amino 
acid derivatives, including a set ofMTM SA Trp derivatives 
some of which may be isotope-labeled variants to be used to 
IC50 
(nM) 
MTM 
MTMSK 
MTMS 
A-Trp 
MTMS 
A-Phe 
MTMS 
A-
Trypta-
mine 
MTMS 
A-5-Br-
Trp 
MTMS 
A-Me 
ester 
MTMS 
A-5-
0Me 
Tryp-
arnine 
MTMS 
A-Tyr 
MTMS 
A-
Serotonin 
TC 
32 5838 
28 43 
23 23 
18 10 
110 439 
29 15 
67 193 
73 78 
133 170 
667 690 
MTM- 6221 
Lys-
2PGs 
Example 2 
In Vitro Cell Toxicity Assays 
The cytotoxicity of a subgroup of the MTM SA analogues 
was tested against various Ewing sarcoma cell lines and 
non-Ewing sarcoma cell lines over a 72 hour period. Each 
analogue was checked individually with a range of concen-
trations to determine the IC50 of the molecule in actively 
growing cell cultures. For comparison, the cytotoxicity of 
MTM and MTM SK, an analogue discovered previously and 
found to be more active than the regular MTM were also 
investigated. The IC50 values are shown in Table 2 below. 
TABLE 2 
IC 50 values of MTM Analogs in Various Ewing Sarcoma and Non-Ewing Sarcoma Cell lines 
EWING SARCOMA CELL LINES NON-EWING SARCOMA CELL LINES 
SK- RH ES ES ES ES ES DU HCT- OVCAR-
ES-1 A673 TC71 RDES 30 -2 -3 -4 -7 -8 A549 U118 PC3 145 C42 VCaP 116 
26 36 25 36 47 42 51 22 32 37 63 48 57 31 81 33 29 26 
25 37 31 40 62 39 56 32 42 44 30 37 32 89 36 31 29 
38 44 34 39 48 63 64 33 41 40 87 56 45 31 96 20 23 72 
109 94 136 182 363 35 61 59 398 32 21 
226 78 155 216 90 86 97 196 76 
219 68 159 210 102 76 50 316 59 
86 46 76 90 41 51 47 99 38 
63 58 84 157 63 79 75 84 58 
306 130 263 266 138 189 171 867 231 
612 671 749 658 610 753 676 >3000 916 
mark hot-spots of interaction. As shown in FIG. 2, MTM SA 
can be isolated either from mutant M7W1 (20 mg/L) or 
enzymatically converted from premithramycin B, which is 
produced at 100 mg/L from the M704 mutant. Exemplary 
Natural products are not always optimized for human 
65 purposes. Combining biosynthetic derivatization with 
chemical synthesis produces unique molecules unattainable 
by either method individually. Thus, a combination of these 
US 9,447,135 B2 
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methods was used to modifY the relatively inactive MTM 
SA that is accumulated alongside the biologically improved 
MTM analogues MTM SK and MTM SDK. The latter two 
molecules, which are both considerably more active and 
significantly less toxic than the natural product MTM itself, 5 
pointed in the direction that 3-side chain modifications can 
be advantageous. The modification of the 3-side chain of 
MTM SA with amino acid derivatives yielded several active 
compounds with the MTM SA-Trp and MTM SA-Phe, 
which exhibit high cytotoxicity against Ewing sarcoma cells 10 
and cancer cell specificity. 
Example 3 
32 
analogues display higher affinity for A-form DNA (e.g. 
Kd=2.7 f.LM for GGGATCCC (SEQ ID N0:04)), than for 
B-form DNA (e.g. Kd>15 f.LM for GGAATTCC (SEQ ID 
N0:05). 
EWS-FLI1 and several constructs of FLil DNA binding 
domain (DBD) were expressed in E. coli and purified to 
homogeneity by a combination of N?+-chelating and size 
exclusion chromatography. EWS-FLI1 required refolding, 
as described previously (Uren eta!. (2004) Biochemistry 43, 
13579-89), whereas FLI1 DBD were expressed as soluble 
proteins free from aggregation (not shown). AnN-terminal 
deca-His tag (SEQ ID NO: 11) was cleaved by Prescission 
protease. These proteins displayed robust binding to con-
sensus DNA containing the central GGAA (SEQ ID N0:06) 
Interaction Between MTM and the DNA Binding 
Domain of EWS-FLI1 
15 recognition sequence and to a GGAA (SEQ ID N0:06) 
repeat sequence that is critical for EWS-FLil binding and 
oncogenesis in vivo (not shown). 
A complex ofMTM SA-Trp (a potent and highly selective 
analogue) with a strong binding double-stranded DNA oli-
gomer (with the core sequence GGCC (SEQ ID N0:03)) 20 
was crystallized and the crystal structure of the complex was 
determined at 2.0 A resolution. This crystal structure of the 
MTM-DNA complex provided a view of DNA recognition 
by MTM in atomic detail. The crystal structure of the 
complex showed that MTM SA-Trp is bound to DNA as a 25 
dimer, whose monomers are coordinated together by a 
divalent metal ion, consistent with previous NMR-molecular 
dynamics studies. Only five hydrogen bonds per MTM 
monomer are observed between MTM SA-Trp and DNA 
bases (direct and water-mediated), and they constitute a very 30 
minor fraction of the intermolecular contacts and do not 
appear to be sequence-specific. Indeed, MTM SA binds a 
variety of DNA sequences, as previously shown (Hampshire 
Example 5 
MTM SA Trp-FLI1 DBD-DNA Complex 
The FLil DBD, which is the DNA interacting part of 
EWS-FLI1, is highly conserved in the ETS family of tran-
scription factors, which include ERG, another protein found 
as a fusion with EWS in Ewing sarcomas. A recently 
reported crystal structure of ERG DBD in complex with the 
consensus DNA containing GGAA (SEQ ID N0:06) core 
(Regan eta!. (2013) Proceedings of the National Academy 
of Sciences of the United States of America 110, 133 7 4-9), 
shows that ERG DBD is bound in the major groove of the 
GGAA (SEQ ID N0:06) region, with the minor groove 
immediately upstream widened and A-form like. Because 
MTM binds to the minor groove of A-form DNA and ERG 
DBD, like FLI1 DBD, binds in the nearby major groove, 
binding ofMTM and EWS-FLil to DNA is not competitive, 
but cooperative. Indeed, the model of MTM SA Trp posi-
tioned in (and stabilizing) the widened groove of the ERG 
DBD-DNA complex as observed in the crystal structure 
shows that the drug and the protein do not clash. The 
structural and biochemical data indicate that MTM and 
EWS-FLI1 bind to distinct neighboring structural regions of 
DNA via cooperative binding. Furthermore, the Trp side 
chain ofMTM SA Trp and the terminal sugar moiety ofthe 
et a!. (2008) Biochimie 90, 988-98). The majority of inter-
molecular contacts are made between the drug and the DNA 35 
backbone as MTM SA-Trp is bound to the minor groove of 
the DNA. Therefore, the DNA backbone conformation is 
likely a determining factor in MTM-DNA binding. Notably, 
the DNA in this structure is A-form, rather than B-form, 
providing a wide minor groove and a distinct relative 40 
base-pair disposition. To determine whether this DNA con-
formation is induced by MTM, the DNA was crystallized 
alone and its structure was determined at 1.65 A resolution. 
The unbound DNA, similar to bound DNA, is A-form, 
suggesting that it is the A-form of the DNA and not the 
sequence alone (MTM is thought to bind GC-rich DNA) that 
45 disaccharide tail of MTM interact with ERG DBD. This 
cooperative binding is responsible for the observed 1) highly 
potent (low-nM) antagonism ofEWS-FLI1 by MTM and its 
analogues (FIG. 9), despite much weaker affinity (low-f.LM, 
at best) ofMTM for DNA in the absence of other factors and 
is a determinant of MTM-DNA binding. Notably, the sol-
vent-exposed 3-side chain of MTM SA-Trp bearing the Trp 
residue protrudes away from the DNA; it is positioned 
appropriately for interacting with DNA-binding factors. 
Example 4 
50 2) modulation of potency and anti-Ewing sarcoma selectiv-
ity in cell culture assays by modifications of the 3-side chain 
ofMTM. 
Binding of MTM/Analogues and EWS-FLI1/FLI1 
DBD to DNA 55 
MTM and its analogues are intrinsically fluorescent and 
their fluorescence decreases upon divalent metal-dependent 
dimerization. This property was used to establish (by titra-
tion of MgC12 into MTM/analogues) that at physiological 60 
salt concentration (5 mM MgC12, 100 mM NaCI), MTM 
analogues are dimeric (not shown). The fluorescence of 
dimeric MTM is strongly (6-fold) enhanced upon DNA 
binding. By monitoring this fluorescence enhancement, the 
ability of MTM/analogues to bind several known A-form 65 
and B-form DNA oligomers was tested. In agreement with 
the crystal structure data, it was shown that MTM and its 
Example 6 
Crystallization, Data Collection and Crystal 
Structure Determination of MTM SA Trp-DNA 
Complex 
1 f.LL drops containing a mixture of 2 mM MTM SA Trp 
(diluted from a 20 mM DMSO stock) and 2 mM of 10-mer 
palindromic DNA (forms 1 mM of double-stranded DNA 
oligonucleotide by self-annealing in 10 mM sodium cacody-
late, pH 6.5) having the sequence: 5'-AGAGGCCTCT-3' 
(SEQ ID N0:9) in 10 mM ZnC12 and 1 mM spermidine, 
were set up as hanging drops over 1 mL of the reservoir 
solutions of varying concentrations of MPD in the range 
US 9,447,135 B2 
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10-20% MPD. The crystals appeared within a week. The 
crystals were rapidly frozen in liquid nitrogen directly from 
the drop. The X-ray diffraction data were collected at the 
Advanced Photon Source, at Argonne National Laboratory. 
The crystal structure was determined by the single anoma- 5 
lous dispersion (SAD) method, by using the anomalous 
signal from Zn2+. The crystal structure of MTM SA Trp-
DNA complex was refined to the resolution of 2 A. The 
crystals contain two complexes of mithramycin dimer with 
and MTM SA-Trp yielded 9-fold selectivity against Ewing 
sarcoma cells relative to non-Ewing cells (FIG. 9, right 
panel). MTM SA-Phe was surprisingly found to be even 
more potent and highly selective in killing of Ewing sar-
coma cells than other MTM SA derivatives. As shown in 
FIG. 10, MTM SA-Phe showed significantly improved 
selectivity in the context of a target ETS transcription factor 
containing a DNA binding domain of SEQ ID NO:Ol or 
SEQ ID N0:02. 
double-stranded DNA in the asymmetric unit. 10 Example 9 
Example 7 
Modeling the Structure of the Ternary Complex of 
MTM SA Trp-DNA-ERG DNA Binding Domain 
An approximate model of a ternary complex of MTM 
SA-DNA-ERG DBD was constructed. The ERG DBD is 
15 
The Effect of MTM and its Analogues on 
EWS-FLI1-Mediated Transcription 
Studies were conducted using MTM and lead analogs 
(mithramycin-SK (MTM-SK), mithramycin-SA-tryptophan 
(MTM-SA-Trp ), and mithramycin-SA-phenylalanine 
(MTM-SA-Phe)). EWS-FLil promoter occupancy was 
nearly identical (with 98% sequence identity) to FLil DBD 
and MTM SA analogues are similarly active against EWS- 20 
ERG and EWS-FLI1 tumor cells. The atomic coordinates for 
investigated using chromatin immune precipitation real time 
PCR (ChiP-RTPCR). The effect of drug treatment on 
expression of genes controlled by EWSFLI1 was evaluated 
all components of the model are given below. The side chain 
of the MTM SA molecule directly interacts with ERG. 
Specifically, the MTM interacting residues in ERG are: 
Tyr356, Lys363, His365, Gly366, Lys367, Arg368, Tyr369, 
Ala370. 
FLI1 (SEQ ID NO: 07, FIG. 6) and ERG (SEQ ID N0:08, 
FIG. 7) contain nearly identical DNA binding domains and, 
therefore, all observations in this study that apply to the 
ERG DNA binding domain, apply to the FLI1 DNA binding 
domain. Accordingly, the MTM interacting residues ofFLI1 
are: Tyr343, Lys350, His352, Gly353, Lys354, Arg355, 
Tyr356, Ala357 of SEQ ID N0:07. For both ERG and FLil, 
the MTM interacting residues are within the DNA binding 
domains of these proteins and correspond to residues Tyr68, 
Lys75, His77, Gly78, Lys79, Arg80, Tyr81, Ala82 of SEQ 
ID N0:01 & SEQ ID N0:02, provided in FIG. 8. 
Example 8 
Selectivity Assays-Ewing Sarcoma Cells Versus 
Non-Ewing Sarcoma Cells 
MTM analogues MTM SA-Ala and MTM SA-Trp display 
higher selectivity than MTM against Ewing sarcoma cells 
relative to non-Ewing cells (FIG. 9). Cytotoxicity of MTM 
and its analogues against a panel of actively growing Ewing 
sarcoma (TC32, 5838, SKES1) and non-Ewing (A459 (lung) 
and PC3 (prostate)) cancer cell lines were measured (72 hr). 
MTM displayed an IC50=15 nM against the Ewing sarcoma 
panel. Remarkably, it was subsequently found that two 
MTM analogues, MTM SA-Ala and MTM SA-Trp show 
3-fold higher selectivity than does MTM against Ewing 
sarcoma relative to non-Ewing cell lines (FIG. 9), with 
MTM SA-Ala being about 200-fold less potent than MTM, 
while MTM SA-Trp is about 3-fold more potent as well as 
3-fold more selective than MTM against Ewing sarcoma 
cells. The modifications of the 3-side chain in MTM SA-Ala 
<160> NUMBER OF SEQ ID NOS, 11 
<210> SEQ ID NO 1 
<211> LENGTH, 98 
<212> TYPE, PRT 
SEQUENCE LISTING 
by quantitative real-time PCR (qRT-PCR) (FIG. 11). The 
effect of treatment with 100 nM of drug for 24 hours on cell 
cycle distribution was also compared among analogs (FIG. 
25 12(b)). In vitro efficacy was evaluated by estimating GI50 
parameters (72-hr) (FIG. 12(a)). In addition, the maximum 
tolerated dose (MTD) and the effect of treatment on plasma 
total-calcium were used to assess relative toxicity in mice. 
EWS-FLI1 promoter occupancy upstream from Nr0b1, 
30 Tgfbr2, and Rcorl genes was evaluated in Ewing sarcoma 
cells (TC32 cells) by ChiP-RTPCR. MTM and MTM-SA-
Trp analog destabilized FLil binding to all three promoters 
and MTM-SA-Trp was shown to be the most destabilizing. 
Comparatively, MTM-SK appears to mostly stabilize FLil. 
35 Additionally, qRTPCR showed that MTM and its analogs 
efficiently down-regulated mRNA expression in a dose 
dependent manner (rank-order of efficiency: MTM-SA-
Trp>MTM=MTM-SK). (FIG. 11). These data were in 
accord with the in vitro cytotoxicity data that show MTM-
40 SA-Trp has relatively higher potency (lower GI50) among 
Ewing cell lines (n=8) as compared to other analogs. (FIG. 
12(a)). Furthermore, the effect of drug treatment appears to 
lead to differences in cell-cycle progression. MTM and 
MTM-SK treated TC32 cells were primarily in G1/G2 
45 phase, whereas MTM-SA-Trp treated cells showed 
increased S-phase accumulation. (FIG. 12(b)). 
Only the preferred embodiment of the present invention 
and examples of its versatility are shown and described in 
the present disclosure. It is to be understood that the present 
50 invention is capable of use in various other combinations 
and environments and is capable of changes or modifications 
within the scope of the inventive concept as expressed 
herein. Thus, for example, those skilled in the art will 
recognize, or be able to ascertain, using no more than routine 
55 experimentation, numerous equivalents to the specific sub-
stances, procedures and arrangements described herein. 
Such equivalents are considered to be within the scope of 
this invention, and are covered by the following claims. 
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<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polypeptide 
<400> SEQUENCE, 1 
Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe Leu Leu Glu Leu Leu 
1 5 10 15 
Ser Asp Ser Ala Asn Ala Ser Cys Ile Thr Trp Glu Gly Thr Asn Gly 
20 25 30 
Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala Arg Arg Trp Gly Glu 
35 40 45 
Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys Leu Ser Arg Ala Leu 
50 55 60 
Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys Val His Gly Lys Arg 
65 70 75 80 
Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala Gln Ala Leu Gln Pro 
85 90 95 
His Pro 
<210> SEQ ID NO 2 
<211> LENGTH, 98 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polypeptide 
<400> SEQUENCE, 2 
Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe Leu Leu Glu Leu Leu 
1 5 10 15 
Ser Asp Ser Ser Asn Ser Ser Cys Ile Thr Trp Glu Gly Thr Asn Gly 
20 25 30 
Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala Arg Arg Trp Gly Glu 
35 40 45 
Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys Leu Ser Arg Ala Leu 
50 55 60 
Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys Val His Gly Lys Arg 
65 70 75 80 
Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala Gln Ala Leu Gln Pro 
85 90 95 
His Pro 
<210> SEQ ID NO 3 
<211> LENGTH, 4 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 3 
ggcc 
<210> SEQ ID NO 4 
<211> LENGTH, 8 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
36 
4 
US 9,447,135 B2 
37 
-continued 
<400> SEQUENCE, 4 
gggatccc 
<210> SEQ ID NO 5 
<211> LENGTH, 8 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 5 
ggaattcc 
<210> SEQ ID NO 
<211> LENGTH, 4 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 
ggaa 
<210> SEQ ID NO 7 
<211> LENGTH, 452 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polypeptide 
<400> SEQUENCE, 7 
Met Asp Gly Thr Ile Lys Glu Ala Leu Ser Val Val Ser Asp Asp Gln 
1 5 10 15 
Ser Leu Phe Asp Ser Ala Tyr Gly Ala Ala Ala His Leu Pro Lys Ala 
20 25 30 
Asp Met Thr Ala Ser Gly Ser Pro Asp Tyr Gly Gln Pro His Lys Ile 
35 40 45 
Asn Pro Leu Pro Pro Gln Gln Glu Trp Ile Asn Gln Pro Val Tyr Val 
50 55 60 
Asn Val Lys Arg Glu Tyr Asp His Met Asn Gly Ser Arg Glu Ser Pro 
65 70 75 80 
Val Asp Cys Ser Val Ser Lys Cys Ser Lys Leu Val Gly Gly Gly Glu 
85 90 95 
Ser Asn Pro Met Asn Tyr Asn Ser Tyr Met Asp Glu Lys Asn Gly Pro 
100 105 110 
Pro Pro Pro Asn Met Thr Thr Asn Glu Arg Arg Val Ile Val Pro Ala 
115 120 125 
Asp Pro Thr Leu Trp Thr Gln Glu His Val Arg Gln Trp Leu Glu Trp 
130 135 140 
Ala Ile Lys Glu Tyr Ser Leu Met Glu Ile Asp Thr Ser Phe Phe Gln 
145 150 155 160 
Asn Met Asp Gly Lys Glu Leu Cys Lys Met Asn Lys Glu Asp Phe Leu 
165 170 175 
Arg Ala Thr Thr Leu Tyr Asn Thr Glu Val Leu Leu Ser His Leu Ser 
180 185 190 
Tyr Leu Arg Glu Ser Ser Leu Leu Ala Tyr Asn Thr Thr Ser His Thr 
38 
8 
8 
4 
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-continued 
195 200 205 
Asp Gln Ser Ser Arg Leu Ser Val Lys Glu Asp Pro Ser Tyr Asp Ser 
210 215 220 
Val Arg Arg Gly Ala Trp Gly Asn Asn Met Asn Ser Gly Leu Asn Lys 
225 230 235 240 
Ser Pro Pro Leu Gly Gly Ala Gln Thr Ile Ser Lys Asn Thr Glu Gln 
245 250 255 
Arg Pro Gln Pro Asp Pro Tyr Gln Ile Leu Gly Pro Thr Ser Ser Arg 
260 265 270 
Leu Ala Asn Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe Leu Leu 
275 280 285 
Glu Leu Leu Ser Asp Ser Ala Asn Ala Ser Cys Ile Thr Trp Glu Gly 
290 295 300 
Thr Asn Gly Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala Arg Arg 
305 310 315 320 
Trp Gly Glu Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys Leu Ser 
325 330 335 
Arg Ala Leu Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys Val His 
340 345 350 
Gly Lys Arg Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala Gln Ala 
355 360 365 
Leu Gln Pro His Pro Thr Glu Ser Ser Met Tyr Lys Tyr Pro Ser Asp 
370 375 380 
Ile Ser Tyr Met Pro Ser Tyr His Ala His Gln Gln Lys Val Asn Phe 
385 390 395 400 
Val Pro Pro His Pro Ser Ser Met Pro Val Thr Ser Ser Ser Phe Phe 
405 410 415 
Gly Ala Ala Ser Gln Tyr Trp Thr Ser Pro Thr Gly Gly Ile Tyr Pro 
420 425 430 
Asn Pro Asn Val Pro Arg His Pro Asn Thr His Val Pro Ser His Leu 
435 440 445 
Gly Ser Tyr Tyr 
450 
<210> SEQ ID NO 8 
<211> LENGTH, 462 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polypeptide 
<400> SEQUENCE, 8 
Met Ile Gln Thr Val Pro Asp Pro Ala Ala His Ile Lys Glu Ala Leu 
1 5 10 15 
Ser Val Val Ser Glu Asp Gln Ser Leu Phe Glu Cys Ala Tyr Gly Thr 
20 25 30 
Pro His Leu Ala Lys Thr Glu Met Thr Ala Ser Ser Ser Ser Asp Tyr 
35 40 45 
Gly Gln Thr Ser Lys Met Ser Pro Arg Val Pro Gln Gln Asp Trp Leu 
50 55 60 
Ser Gln Pro Pro Ala Arg Val Thr Ile Lys Met Glu Cys Asn Pro Ser 
65 70 75 80 
Gln Val Asn Gly Ser Arg Asn Ser Pro Asp Glu Cys Ser Val Ala Lys 
85 90 95 
40 
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-continued 
Gly Gly Lys Met Val Gly Ser Pro Asp Thr Val Gly Met Asn Tyr Gly 
100 105 110 
Ser Tyr Met Glu Glu Lys His Met Pro Pro Pro Asn Met Thr Thr Asn 
115 120 125 
Glu Arg Arg Val Ile Val Pro Ala Asp Pro Thr Leu Trp Ser Thr Asp 
130 135 140 
His Val Arg Gln Trp Leu Glu Trp Ala Val Lys Glu Tyr Gly Leu Pro 
145 150 155 160 
Asp Val Asn Ile Leu Leu Phe Gly Asn Ile Asp Gly Lys Glu Leu Cys 
165 170 175 
Lys Met Thr Lys Asp Asp Phe Gln Arg Leu Thr Pro Ser Tyr Asn Ala 
180 185 190 
Asp Ile Leu Leu Ser His Leu His Tyr Leu Arg Glu Thr Pro Leu Pro 
195 200 205 
His Leu Thr Ser Asp Asp Val Asp Lys Ala Leu Gln Asn Ser Pro Arg 
210 215 220 
Leu Met His Ala Arg Asn Thr Asp Leu Pro Tyr Glu Pro Pro Arg Arg 
225 230 235 240 
Ser Ala Trp Thr Gly His Gly His Pro Thr Pro Gln Ser Lys Ala Ala 
245 250 255 
Gln Pro Ser Pro Ser Thr Val Pro Lys Thr Glu Asp Gln Arg Pro Gln 
260 265 270 
Leu Asp Pro Tyr Gln Ile Leu Gly Pro Thr Ser Ser Arg Leu Ala Asn 
275 280 285 
Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe Leu Leu Glu Leu Leu 
290 295 300 
Ser Asp Ser Ser Asn Ser Ser Cys Ile Thr Trp Glu Gly Thr Asn Gly 
305 310 315 320 
Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala Arg Arg Trp Gly Glu 
325 330 335 
Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys Leu Ser Arg Ala Leu 
340 345 350 
Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys Val His Gly Lys Arg 
355 360 365 
Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala Gln Ala Leu Gln Pro 
370 375 380 
His Pro Pro Glu Ser Ser Leu Tyr Lys Tyr Pro Ser Asp Leu Pro Tyr 
385 390 395 400 
Met Gly Ser Tyr His Ala His Pro Gln Lys Met Asn Phe Val Ala Pro 
405 410 415 
His Pro Pro Ala Leu Pro Val Thr Ser Ser Ser Phe Phe Ala Ala Pro 
420 425 430 
Asn Pro Tyr Trp Asn Ser Pro Thr Gly Gly Ile Tyr Pro Asn Thr Arg 
435 440 445 
Leu Pro Thr Ser His Met Pro Ser His Leu Gly Thr Tyr Tyr 
450 455 460 
<210> SEQ ID NO 9 
<211> LENGTH, 10 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 9 
42 
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-continued 
agaggcctct 
<210> SEQ ID NO 10 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
10 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
6xHis tag 
<400> SEQUENCE, 10 
His His His His His His 
1 5 
<210> SEQ ID NO 11 
<211> LENGTH, 10 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
10xHis tag 
<400> SEQUENCE, 11 
His His His His His His His His His His 
1 5 10 
What is claimed is: 4. The MTM SA derivative of claim 2, wherein NR1 R2 
1. An MTM SA derivative having the following formula: 30 form a tryptophan (Trp) conjugate or an ester derivative 
thereof. 
35 
or a pharmaceutically acceptable salt thereof; wherein Z 40 
represents 0, S, N-R'; R and R' represent, for each 
occurrence, H, alkyl, heterocyclic, aryl, heteroaryl, 
provided that R is not H when Z is 0; ZR taken together 
represents an organic residue; and wherein MTM1 
represents the fused ring portion of the mithramycin 45 
structure and can include different sugars or sugar 
chains. 
5. The MTM SA derivative of claim 3 wherein the 
phenylalanine is substituted with an indole alkyl group. 
6. The MTM SA derivative of claim 4 wherein the 
tryptophan is substituted with a phenyl alkyl group. 
7. A method of preparing the MTM SA derivative of claim 
2, the method comprising coupling the terminal carboxylic 
acid group of MTM SA with an amine. 
8. A method of treating cancer or neuro-disease in a 
patient in need thereof, the method comprising administer-
ing to the patient a therapeutically effective amount of the 
MTM SA derivative or a pharmaceutically acceptable salt 
thereof of claim 1. 
9. The method of claim 8, wherein the method comprises 
treating Ewing sarcoma. 
10. The method of claim 8, wherein the method comprises 
treating lung cancer. 2. The MTM SA derivative according to claim 1 having 
the following formula: 11. The method of claim 8, wherein the method comprises 
50 treating colon cancer. 
MTM1 R2 
12. The method of claim 9 wherein the MTM SA deriva-
tive is a substituted or unsubstituted MTM SA-Trp or an 
ester derivative thereof or a pharmaceutically acceptable salt 
thereof. 
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wherein R1 and R2 can be the same or different and each 
of R1 and R2 can be an H, an amino acid conjugate or 
an ester derivative thereof, a lower straight chain or 60 
branched alkyl unsubstituted or substituted with one or 
more amino, alkyl amino, alkylcarboxyl, alkoxyl, alky-
lcarbonyl, hydroxyl, thio, alkyldisulfide, halo, provided 
that R1 and R2 are not both H simultaneously. 
3. The MTM SA derivative of claim 2, wherein NR1 R2 65 
form a phenylalanine (Phe) conjugate or an ester derivative 
thereof. 
tive is a substituted or unsubstituted MTM SA-Phe or an 
ester derivative thereof or a pharmaceutically acceptable salt 
thereof. 
14. A method for selectively modulating the activity of a 
target ETS transcription factor in a patient in need thereof, 
including administering to the patient a therapeutically 
effective amount of an MTM SA derivative or a pharma-
ceutically acceptable salt thereof of claim 2. 
15. The method of claim 14, wherein the MTM SA 
derivative is a substituted or unsubstituted MTM SA-Phe or 
an ester derivative thereof or a pharmaceutically acceptable 
salt thereof. 
US 9,447,135 B2 
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16. The method of claim 14, wherein the MTM SA 
derivative is a substituted or unsubstituted MTM SA-Trp or 
an ester derivative thereof or a pharmaceutically acceptable 
salt thereof. 
* * * * * 
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